

Approved



**Ethiopia**  
**Country Operational Plan**  
**FY 2018**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		549,395		549,395	142,857	692,252
USAID		20,201,891	0	20,201,891	19,478,432	39,680,323
DOD		0		0	363,265	363,265
HHS/CDC	2,787,500	41,981,800		44,769,300	5,935,802	50,705,102
HHS/HRSA		400,000		400,000	0	400,000
State/AF		200,000		200,000	3,500,000	3,700,000
State/PRM		770,072		770,072	0	770,072
State/SGAC		4,709,932		4,709,932	0	4,709,932
<b>Total</b>	<b>2,787,500</b>	<b>68,813,090</b>	<b>0</b>	<b>71,600,590</b>	<b>29,420,356</b>	<b>101,020,946</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							Total
	State	HHS/CDC	HHS/HRSA	State/AF	State/SGAC	State/PRM	USAID	
CIRC	2,948	899,659	0	0	0	113,006	100,000	1,115,613
HBHC	7,752	3,740,097	0	0	0	39,379	584,434	4,371,662
HKID	15,976	0	0	0	0	0	13,229,711	13,245,687
HLAB	0	1,927,986	80,000	0	0	0	292,097	2,300,083
HMBL	0	0	0	0	0	0	0	0
HMIN	2,948	0	0	0	0	0	0	2,948
HTXD	0	0	0	10,000	0	0	0	10,000
HTXS	7,097	20,339,039	0	170,000	4,083,315	319,958	4,383,256	29,302,665
HVAB	2,787	0	0	0	0	0	0	2,787
HVCT	9,242	4,702,662	0	0	0	63,992	175,329	4,951,225

Approved



HVMS	452,792	4,855,686					0	<b>5,308,478</b>
HVOP	22,035	421,198	0	0	0	164,823	0	<b>608,056</b>
HVSI	9,327	1,216,300	0	0	626,617	0	0	<b>1,852,244</b>
HVTB	1,394	2,484,238	0	0	0	9,845	0	<b>2,495,477</b>
IDUP	0	0	0	0	0	0	0	<b>0</b>
MTCT	10,915	7,388	0	0	0	0	0	<b>18,303</b>
OHSS	1,394	7,388	320,000	0	0	0	735,743	<b>1,064,525</b>
PDCS	1,394	1,466,197	0	10,000	0	39,379	116,887	<b>1,633,857</b>
PDTX	1,394	2,701,462	0	10,000	0	19,690	584,434	<b>3,316,980</b>
	<b>549,395</b>	<b>44,769,300</b>	<b>400,000</b>	<b>200,000</b>	<b>4,709,932</b>	<b>770,072</b>	<b>20,201,891</b>	<b>71,600,590</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	3,471,861
HKID	13,229,711
HVTB	2,203,950
PDCS	1,438,216
<b>Total Technical Area Planned Funding:</b>	<b>20,343,738</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	2,174,375
HVSI	1,652,229
OHSS	1,055,743
<b>Total Technical Area Planned Funding:</b>	<b>4,882,347</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	1,097,885
HMBL	0
HMIN	0
HVAB	0
HVCT	4,381,521
HVOP	514,823
IDUP	0
MTCT	0
<b>Total Technical Area Planned Funding:</b>	<b>5,994,229</b>

Approved



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>
HTXD	10,000
HTXS	27,747,123
PDTX	3,003,758
<b>Total Technical Area Planned Funding:</b>	<b>30,760,881</b>



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
	Number of new ANC and L&D clients	0
	By Age (Denominator): Unknown Age	0
	By Age (Denominator): <10	0
	By Age (Denominator): 10-14	0
	By Age (Denominator): 15-19	0
	By Age (Denominator): 20-24	0
	By Age (Denominator): 50+	0
	By known positives: <Unknown Age	0
	By known positives: <10	0
	By known positives: 10-14	0
	By known positives: 15-19	0
	By known positives: 20-24	0
	By known positives: 50+	0
	By new positives: Unknown Age	0
By new positives: <10	0	
By new positives: 10-14	0	
By new positives: 15-19	0	



	By new positives: 20-24	0
	By new positives: 50+	0
	By new negatives: Unknown Age	0
	By new negatives: <10	0
	By new negatives: 10-14	0
	By new negatives: 15-19	0
	By new negatives: 20-24	0
	By new negatives: 50+	0
	By Age (Numerator): Unknown Age	0
	By Age (Numerator): <10	0
	By Age (Numerator): 10-14	0
	By Age (Numerator): : 15-19	0
	By Age (Numerator): 20-24	0
	By Age (Numerator): 50+	0
	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	0
	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	0
	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	0
	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	0
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Known at Entry Positive	0
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Negative	0
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Positive	0
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female,	0



	Known at Entry Positive	
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	0
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	0
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	0
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	0
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	0
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	0
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	0
	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	0
	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	0
	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	0
	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	0
	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	0
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who	n/a





	received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	11,389
	New on ART	3,614
	Already on ART at beginning of current pregnancy	7,775
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,228
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
	New on ART	420
	Already on ART at beginning of current pregnancy	808
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	31,415
	By Age: 2 months - 9 years	13
	By Age: 10-14	19,015



	By Age: 15-19	6,825
	By Age: 20-24	3,690
	By Age: 25-29	1,752
	By Age: 50+	89
	By circumcision technique: Surgical VMMC	27,361
	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	31
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	469
	By Age: 0-60 Days	469
	By circumcision technique: Surgical VMMC	469
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Male 20-24	0
	Male 50+	0
	Female 15-19	0
	Female 20-24	0
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	0
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	0
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	0
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	0
PP_PREV_DSD	PP_PREV_DSD Percentage of the	n/a



	target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	112,209
	Age/sex: 10-14 Male	0
	Age/sex: 15-19 Male	3,655
	Age/sex: 20-24 Male	24,014
	Age/sex: 50+ Male	1,929
	Age/sex: 10-14 Female	0
	Age/sex: 15-19 Female	8,540
	Age/sex: 20-24 Female	9,289
	Age/sex: 50+ Female	220
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	8,524
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	18,057
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	8,524
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	15,594
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	1,121
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	7,392
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	291
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	4,922



KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	45,431
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0



	<p>By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>0</p>
	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>45,431</p>
	<p>By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>0</p>
	<p>By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>0</p>
	<p>By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual</p>	<p>0</p>



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	310,337
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	2,584
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	17
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	2,185
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	10
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	2,835
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	44
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	2,353
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	35
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	7,457
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	120
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	5,337
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	81
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	891



	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	13
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,050
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	14
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	369
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	501
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Inpatient: <1, Negative	233
	Service Delivery Point (Facility) Inpatient: <1, Positive	1
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,974
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	34
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	0
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	0
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	0



	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	0
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	0
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	0
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	0
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	0
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	0
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	0
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	0
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	0
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	0
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	0
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	0
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	0
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility)	0





	Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Other PITC: <1, Negative	0
	Service Delivery Point (Facility) Other PITC: <1, Positive	0
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	0
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	0
	Service Delivery Point (Facility) Pediatric : <5 Negative	207
	Service Delivery Point (Facility) Pediatric : <5 Positive	5
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	766
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	9
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	792
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	15
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1,277
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	34
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	1,155



	Service Delivery Point (Facility) TB: 15-19, Male, Positive	17
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	2,613
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	232
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	2,970
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	208
	Service Delivery Point (Facility) TB: 50+, Female, Negative	513
	Service Delivery Point (Facility) TB: 50+, Female, Positive	8
	Service Delivery Point (Facility) TB: 50+, Male, Negative	613
	Service Delivery Point (Facility) TB: 50+, Male, Positive	9
	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	23
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	18
	Service Delivery Point (Facility) TB: <1, Negative	9
	Service Delivery Point (Facility) TB: <1, Positive	0
	Service Delivery Point (Facility) TB: 1-9, Negative	507
	Service Delivery Point (Facility) TB: 1-9, Positive	1



	Service Delivery Point (Facility) VMMC: <1, Negative	0
	Service Delivery Point (Facility) VMMC: <1, Positive	0
	Service Delivery Point (Facility) VMMC: 10-14, Negative	0
	Service Delivery Point (Facility) VMMC: 10-14, Positive	0
	Service Delivery Point (Facility) VMMC: 15-19, Negative	0
	Service Delivery Point (Facility) VMMC: 15-19, Positive	0
	Service Delivery Point (Facility) VMMC: 1-9, Negative	0
	Service Delivery Point (Facility) VMMC:	0
	Service Delivery Point (Facility) VMMC: 20-24, Negative	0
	Service Delivery Point (Facility) VMMC: 20-24, Positive	0
	Service Delivery Point (Facility) VMMC: 50+, Negative	0
	Service Delivery Point (Facility) VMMC: 50+, Positive	0
	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	9,846
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	563
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	11,120



	Service Delivery Point (Facility) Index: 10-14, Male, Positive	581
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	2,133
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	122
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	2,163
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	130
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	7,404
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	407
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	4,720
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	290
	Service Delivery Point (Facility) Index: 50+, Female, Negative	7,937
	Service Delivery Point (Facility) Index: 50+, Female, Positive	548
	Service Delivery Point (Facility) Index: 50+, Male, Negative	8,027
	Service Delivery Point (Facility) Index: 50+, Male, Positive	546
	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	57
	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) Index: Unknown Age, Male,	77



	Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Index: <1, Negative	128
	Service Delivery Point (Facility) Index: <1, Positive	5
	Service Delivery Point (Facility) Index: 1-9, Negative	9,005
	Service Delivery Point (Facility) Index: 1-9, Positive	513
	Service Delivery Point (Facility) ANC: <1, Negative	0
	Service Delivery Point (Facility) ANC: <1, Positive	0
	Service Delivery Point (Facility) ANC: 10-14, Negative	0
	Service Delivery Point (Facility) ANC: 10-14, Positive	0
	Service Delivery Point (Facility) ANC: 15-19, Negative	0
	Service Delivery Point (Facility) ANC: 15-19, Positive	0
	Service Delivery Point (Facility) ANC: 1-9, Negative	0
	Service Delivery Point (Facility) ANC: 1-9, Positive	0
	Service Delivery Point (Facility) ANC: 20-24, Negative	0
	Service Delivery Point (Facility) ANC: 20-24, Positive	0
	Service Delivery Point (Facility) ANC: 50+, Negative	0



	Service Delivery Point (Facility) ANC: 50+, Positive	0
	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	0
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	0
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	0
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	0
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	0
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	0
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	0
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	0
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	0
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	0
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	0



	Service Delivery Point (Facility) VCT: 50+, Male, Negative	0
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	0
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) VCT: <1, Negative	0
	Service Delivery Point (Facility) VCT: <1, Positive	0
	Service Delivery Point (Facility) VCT: 1-9, Negative	0
	Service Delivery Point (Facility) VCT: 1-9, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Female, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Female, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Male, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Male, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 15-19, Female, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R	0



	result 15-19, Female, Positive	
	HTS_TST_N_TA_EW_Age_Sex_R result 15-19, Male, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R result 15-19, Male, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R result 1-9, Unknown Sex, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R result 1-9, Unknown Sex, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R result <1, Unknown Sex, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R result <1, Unknown Sex, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R result 20-24, Female, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R result 20-24, Female, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R result 20-24, Male, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R result 20-24, Male, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R result 25-29, Female, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R result 25-29, Female, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R result 25-29, Male, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R result 25-29, Male, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R result 30-34, Female, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R result 30-34, Female, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R	0





	esult 30-34, Male, Negative	
	HTS_TST_N_TA_EW_Age_Sex_R esult 30-34, Male, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Female, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Female, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Male, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Male, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Female, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Female, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Male, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Male, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 50+, Female, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 50+, Female, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 50+, Male, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 50+, Male, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult Unknown Age, Female, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R esult Unknown Age, Female, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R	0



	esult Unknown Age, Male, Negative	
	HTS_TST_N_TA_EW_Age_Sex_Result Unknown Age, Male, Positive	0
	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	29,052
	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	2,050
	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	15,958
	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	1,190
	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	2,330
	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	195
	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	8,214
	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	590
	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	11,946
	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	854
	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	10,155
	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	741
	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	8,107
	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	586
	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	10,161



HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Male, Positive	742
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Female, Negative	5,163
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Female, Positive	87
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Male, Negative	5,976
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Male, Positive	94
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Female, Negative	4,376
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Female, Positive	69
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Male, Negative	4,076
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Male, Positive	65
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Female, Negative	4,375
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Female, Positive	69
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Male, Negative	4,077
HTS_TST_N_TA_Inpat_Age_Sex_ Result 35-39, Male, Positive	66
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Female, Negative	3,362
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Female, Positive	48
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Male, Negative	4,805
HTS_TST_N_TA_Inpat_Age_Sex_ Result 40-49, Male, Positive	74



HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	2,427
HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	47
HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	0
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	0



HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	0
HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	0
HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	0
HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	0
HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	0
HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	0
HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	0
HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	0
HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	0
HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Negative	83
HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Positive	0
HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Negative	83
HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Positive	0
HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Negative	83
HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Positive	0
HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	459
HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	8



	HTS_TST_N_TA_STI_Age_Sex_R esult 15-19, Male, Negative	374
	HTS_TST_N_TA_STI_Age_Sex_R esult 15-19, Male, Positive	5
	HTS_TST_N_TA_STI_Age_Sex_R esult 1-9, Unknown Sex, Negative	167
	HTS_TST_N_TA_STI_Age_Sex_R esult 1-9, Unknown Sex, Positive	0
	HTS_TST_N_TA_STI_Age_Sex_R esult 20-24, Female, Negative	2,248
	HTS_TST_N_TA_STI_Age_Sex_R esult 20-24, Female, Positive	73
	HTS_TST_N_TA_STI_Age_Sex_R esult 20-24, Male, Negative	1,314
	HTS_TST_N_TA_STI_Age_Sex_R esult 20-24, Male, Positive	36
	HTS_TST_N_TA_STI_Age_Sex_R esult 25-29, Female, Negative	1,671
	HTS_TST_N_TA_STI_Age_Sex_R esult 25-29, Female, Positive	55
	HTS_TST_N_TA_STI_Age_Sex_R esult 25-29, Male, Negative	1,511
	HTS_TST_N_TA_STI_Age_Sex_R esult 25-29, Male, Positive	42
	HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Female, Negative	1,340
	HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Female, Positive	36
	HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Male, Negative	1,631
	HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Male, Positive	49
	HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Female, Negative	1,343



HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Female, Positive	39
HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Male, Negative	1,633
HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Male, Positive	44
HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Female, Negative	1,705
HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Female, Positive	29
HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Male, Negative	1,836
HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Male, Positive	47
HTS_TST_N_TA_STI_Age_Sex_R esult 50+, Female, Negative	424
HTS_TST_N_TA_STI_Age_Sex_R esult 50+, Female, Positive	2
HTS_TST_N_TA_STI_Age_Sex_R esult 50+, Male, Negative	479
HTS_TST_N_TA_STI_Age_Sex_R esult 50+, Male, Positive	3
HTS_TST_N_TA_STI_Age_Sex_R esult Unknown Age, Female, Negative	0
HTS_TST_N_TA_STI_Age_Sex_R esult Unknown Age, Female, Positive	0
HTS_TST_N_TA_STI_Age_Sex_R esult Unknown Age, Male, Negative	0
HTS_TST_N_TA_STI_Age_Sex_R esult Unknown Age, Male, Positive	0
HTS_TST_N_TA_TBC_Age_Sex_	2,613



	Result 25-29, Female, Negative	
	HTS_TST_N_TA_TBC_Age_Sex_	254
	Result 25-29, Female, Positive	
	HTS_TST_N_TA_TBC_Age_Sex_	2,672
	Result 25-29, Male, Negative	
	HTS_TST_N_TA_TBC_Age_Sex_	228
	Result 25-29, Male, Positive	
	HTS_TST_N_TA_TBC_Age_Sex_	2,588
	Result 30-34, Female, Negative	
	HTS_TST_N_TA_TBC_Age_Sex_	195
	Result 30-34, Female, Positive	
	HTS_TST_N_TA_TBC_Age_Sex_	2,635
	Result 30-34, Male, Negative	
	HTS_TST_N_TA_TBC_Age_Sex_	181
	Result 30-34, Male, Positive	
	HTS_TST_N_TA_TBC_Age_Sex_	1,368
	Result 35-39, Female, Negative	
	HTS_TST_N_TA_TBC_Age_Sex_	66
	Result 35-39, Female, Positive	
	HTS_TST_N_TA_TBC_Age_Sex_	1,407
	Result 35-39, Male, Negative	
	HTS_TST_N_TA_TBC_Age_Sex_	62
	Result 35-39, Male, Positive	
	HTS_TST_N_TA_TBC_Age_Sex_	1,344
	Result 40-49, Female, Negative	
	HTS_TST_N_TA_TBC_Age_Sex_	56
	Result 40-49, Female, Positive	
	HTS_TST_N_TA_TBC_Age_Sex_	1,385
	Result 40-49, Male, Negative	
	HTS_TST_N_TA_TBC_Age_Sex_	48
	Result 40-49, Male, Positive	
	HTS_TST_N_TA_VCT_Age_Sex_	0
	Result 25-29, Female, Negative	
	HTS_TST_N_TA_VCT_Age_Sex_	0





	Result 25-29, Female, Positive	
	HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Male, Negative	0
	HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Male, Positive	0
	HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Female, Negative	0
	HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Female, Positive	0
	HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Male, Negative	0
	HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Male, Positive	0
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Female, Negative	0
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Female, Positive	0
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Male, Negative	0
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Male, Positive	0
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Female, Negative	0
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Female, Positive	0
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Male, Negative	0
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Male, Positive	0
	HTS_TST_N_TA_VMMC_Age_Sex_ Result 25-29, Male, Negative	3,331
	HTS_TST_N_TA_VMMC_Age_Sex_ Result 25-29, Male, Positive	0
	HTS_TST_N_TA_VMMC_Age_Sex	500



	_Result 30-34, Male, Negative	
	HTS_TST_N_TA_VMMC_Age_Sex _Result 30-34, Male, Positive	0
	HTS_TST_N_TA_VMMC_Age_Sex _Result 35-39, Male, Negative	0
	HTS_TST_N_TA_VMMC_Age_Sex _Result 35-39, Male, Positive	0
	HTS_TST_N_TA_VMMC_Age_Sex _Result 40-49, Male, Negative	0
	HTS_TST_N_TA_VMMC_Age_Sex _Result 40-49, Male, Positive	0
HTS_SELF_TA	HTS_SELF_N_TA	4,046
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 10-14, Female, Directly-Assisted	4
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 10-14, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 10-14, Male, Directly-Assisted	4
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 10-14, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 15-19, Female, Directly-Assisted	258
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 15-19, Female, Unassisted	3
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 15-19, Male, Directly-Assisted	222
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 15-19, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Female,	404



	Directly-Assisted	
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Male, Directly-Assisted	372
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 25-29, Female, Directly-Assisted	416
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 25-29, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 25-29, Male, Directly-Assisted	473
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 25-29, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Female, Directly-Assisted	342
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Male, Directly-Assisted	298
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 35-39, Female, Directly-Assisted	338
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 35-39, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS	300



	elfTest 35-39, Male, Directly-Assisted	
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 35-39, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 40-49, Female, Directly-Assisted	255
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 40-49, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 40-49, Male, Directly-Assisted	362
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 40-49, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 50+, Female, Directly-Assisted	87
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 50+, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 50+, Male, Directly-Assisted	86
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 50+, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest Unknown Age, Female, Directly-Assisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest Unknown Age, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest Unknown Age, Male, Directly-Assisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest Unknown Age, Male, Unassisted	0



	HTS_SELF_N_TA_HIVSelfTest Directly-Assisted	3,953
	HTS_SELF_N_TA_HIVSelfTest Unassisted	93
	HTS_SELF_N_TA_HIVSelfTestUs er Unassisted - Other	0
	HTS_SELF_N_TA_HIVSelfTestUs er Unassisted - Self	0
	HTS_SELF_N_TA_HIVSelfTestUs er Unassisted - Sex Partner	0
	HTS_SELF_N_TA_KeyPop_HIVSe lfTest FSW, Directly-Assisted	2,836
	HTS_SELF_N_TA_KeyPop_HIVSe lfTest FSW, Unassisted	0
	HTS_SELF_N_TA_KeyPop_HIVSe lfTest MSM, Directly-Assisted	0
	HTS_SELF_N_TA_KeyPop_HIVSe lfTest MSM, Unassisted	0
	HTS_SELF_N_TA_KeyPop_HIVSe lfTest People in prisons and other enclosed settings, Directly-Assisted	0
	HTS_SELF_N_TA_KeyPop_HIVSe lfTest People in prisons and other enclosed settings, Unassisted	0
	HTS_SELF_N_TA_KeyPop_HIVSe lfTest PWID, Directly-Assisted	0
	HTS_SELF_N_TA_KeyPop_HIVSe lfTest PWID, Unassisted	0
	HTS_SELF_N_TA_KeyPop_HIVSe lfTest TG, Directly-Assisted	0
	HTS_SELF_N_TA_KeyPop_HIVSe lfTest TG, Unassisted	0
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB	100 %



	cases with documented HIV status.	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	11,414
	Total number of registered new and relapsed TB cases, during the reporting period.	11,413
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	450
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,890
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	437
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,343
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	442
	Aggregated Age/Sex: Male 15+	6,073



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	441
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4,437
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	97 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	21,176
	Total number of registered new and relapsed TB cases, during the reporting period.	21,894
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	959
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,469
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8,996



	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	11,819
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,421
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	11,270
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	915
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8,448
HTS_SELF_DSD	HTS_SELF_N_DSD	4,989
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Directly-Assisted	0
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Unassisted	0
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Directly-Assisted	0
	HTS_SELF_N_DSD_Age_Sex_HI	0





	VSelfTest 10-14, Male, Unassisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Directly-Assisted	339
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	142
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Directly-Assisted	936
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	189
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	1,054
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	222
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	938
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	176
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	764
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Directly-Assisted	174
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	672
	HTS_SELF_N_DSD_Age_Sex_HI	192



	VSelfTest 40-49, Male, Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Directly-Assisted	195
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Directly-Assisted	45
	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	4,989
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	30,390
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	227
	Service Delivery Point (Community) Other: 15-19, Female, Positive	6
	Service Delivery Point (Community) Other: 15-19, Male, Negative	87
	Service Delivery Point (Community) Other: 15-19, Male, Positive	4
	Service Delivery Point (Community) Other: 20-24, Female, Negative	812
	Service Delivery Point (Community) Other: 20-24, Female, Positive	29
	Service Delivery Point (Community) Other: 20-24, Male, Negative	133
	Service Delivery Point (Community) Other: 20-24, Male, Positive	13
	Service Delivery Point (Community) Other: 50+, Female, Negative	98
	Service Delivery Point (Community) Other: 50+, Female, Positive	2



	Service Delivery Point (Community) Other: 50+, Male, Negative	88
	Service Delivery Point (Community) Other: 50+, Male, Positive	2
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	0
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	0
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	0
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	0
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
	Service Delivery Point (Facility) TB: 50+, Female, Negative	0
	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
	Service Delivery Point (Facility) TB: 50+, Male, Negative	0



	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) TB: <1, Negative	0
	Service Delivery Point (Facility) TB: <1, Positive	0
	Service Delivery Point (Facility) TB: 1-9, Negative	0
	Service Delivery Point (Facility) TB: 1-9, Positive	0
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	0
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	0
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	0
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	0
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	0



	Service Delivery Point (Facility) Index: 20-24, Male, Negative	0
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	0
	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
	Service Delivery Point (Facility) Index: 50+, Male, Negative	0
	Service Delivery Point (Facility) Index: 50+, Male, Positive	0
	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Index: <1, Negative	0
	Service Delivery Point (Facility) Index: <1, Positive	0
	Service Delivery Point (Facility) Index: 1-9, Positive	0
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	427
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	10
	Service Delivery Point (Community)	682



	Index Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	6
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	402
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	24
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	242
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	15
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	884
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	54
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	402
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	25
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	163
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	9
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	162
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	9
	Service Delivery Point (Community) Index Mod: <1, Negative	85
	Service Delivery Point (Community) Index Mod: <1, Positive	6
	Service Delivery Point (Community)	511



	Index Mod: 1-9, Negative	
	Service Delivery Point (Community) Index Mod: 1-9, Positive	7
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	1,167
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	57
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	298
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	16
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	1,463
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	79
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	445
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	26
	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	732
	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	36
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	295
	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	14
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	0
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	0
	Service Delivery Point (Community)	0



	VCT Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: <1, Positive	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	0
	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	0





HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	0
HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	0
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1,048
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	65
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	318
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	19
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	1,208
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	76
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	322
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	19
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	1,122
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	70
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	321
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	19



HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	1,282
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	80
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	165
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	9
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	905
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	36
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	135
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	12
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	807
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	29
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	136
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	2
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	674
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	23



	Positive	
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	88
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	4
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	232
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	13
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	92
	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	2
	HTS_TST_N_DSD_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_Result <1, Unknown Sex, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_	0



	Result 15-19, Male, Positive	
	HTS_TST_N_DSD_STI_Age_Sex_ Result 1-9, Unknown Sex, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 1-9, Unknown Sex, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Female, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Female, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Male, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Male, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_	0



	Result 40-49, Female, Negative	
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result Unknown Age, Female, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result Unknown Age, Female, Positive	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result Unknown Age, Male, Negative	0
	HTS_TST_N_DSD_STI_Age_Sex_ Result Unknown Age, Male, Positive	0
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Negative	0
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Positive	0
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Male, Negative	0
	HTS_TST_N_DSD_TBC_Age_Sex	0



	_Result 25-29, Male, Positive	
	HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Female, Negative	0
	HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Female, Positive	0
	HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Negative	0
	HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Positive	0
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Negative	0
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Positive	0
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Positive	0
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	0
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	0
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	0
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	0
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Negative	2,336
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Positive	122
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Negative	451
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Positive	25
	HTS_TST_N_DSD_VCTMod_Age_	2,491



	Sex_Result 30-34, Female, Negative	
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	124
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	601
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	29
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	2,198
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	110
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	449
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	21
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	1,463
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	76
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	300
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	15
GEND_GBV_DSD	Number of people receiving post-GBV care	7,442
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3,115



	By type of service: Sexual Violence (Post-Rape Care)	4,279
	By PEP service provision (related to sexual violence services provided)	2,678
	<10, Female, Physical and/or Emotional Violence	31
	<10, Female, Sexual Violence (Post-Rape Care)	42
	<10, Male, Physical and/or Emotional Violence	16
	<10, Male, Sexual Violence (Post-Rape Care)	7
	10-14, Female, Physical and/or Emotional Violence	220
	10-14, Female, Sexual Violence (Post-Rape Care)	243
	10-14, Male, Physical and/or Emotional Violence	271
	10-14, Male, Sexual Violence (Post-Rape Care)	101
	15-19, Female, Physical and/or Emotional Violence	453
	15-19, Female, Sexual Violence (Post-Rape Care)	1,039
	15-19, Male, Physical and/or Emotional Violence	253
	15-19, Male, Sexual Violence (Post-Rape Care)	42
	20-24, Female, Physical and/or Emotional Violence	839
	20-24, Female, Sexual Violence (Post-Rape Care)	1,376
	20-24, Male, Physical and/or	100





	Emotional Violence	
	20-24, Male, Sexual Violence (Post-Rape Care)	5
	50+, Female, Physical and/or Emotional Violence	26
	50+, Female, Sexual Violence (Post-Rape Care)	26
	50+, Male, Physical and/or Emotional Violence	1
	50+, Male, Sexual Violence (Post-Rape Care)	0
	Unknown Age, Female, Physical and/or Emotional Violence	0
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
	Unknown Age, Male, Physical and/or Emotional Violence	0
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	296
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	860
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	1
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	2
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	188



	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	250
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	0
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	1
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	193
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	218
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	0
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	0
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	119
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	140
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	1
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	Number of people receiving post-GBV care	694



	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	275
	By type of service: Sexual Violence (Post-Rape Care)	413
	By PEP service provision (related to sexual violence services provided)	275
	<10, Female, Physical and/or Emotional Violence	2
	<10, Female, Sexual Violence (Post-Rape Care)	2
	<10, Male, Physical and/or Emotional Violence	0
	<10, Male, Sexual Violence (Post-Rape Care)	1
	10-14, Female, Physical and/or Emotional Violence	26
	10-14, Female, Sexual Violence (Post-Rape Care)	26
	10-14, Male, Physical and/or Emotional Violence	41
	10-14, Male, Sexual Violence (Post-Rape Care)	13
	15-19, Female, Physical and/or Emotional Violence	46
	15-19, Female, Sexual Violence (Post-Rape Care)	111
	15-19, Male, Physical and/or Emotional Violence	41
	15-19, Male, Sexual Violence (Post-Rape Care)	1
	20-24, Female, Physical and/or Emotional Violence	68



	20-24, Female, Sexual Violence (Post-Rape Care)	139
	20-24, Male, Physical and/or Emotional Violence	0
	20-24, Male, Sexual Violence (Post-Rape Care)	0
	50+, Female, Physical and/or Emotional Violence	3
	50+, Female, Sexual Violence (Post-Rape Care)	2
	50+, Male, Physical and/or Emotional Violence	0
	50+, Male, Sexual Violence (Post-Rape Care)	0
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	13
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	68
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	0
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	0
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	1
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	13
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	0



	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	0
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	13
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	13
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	0
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	0
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	13
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	13
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	0
	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	497,893
	Age/Sex: 10-14 Male	68,327
	Age/Sex: 15-17 Male	37,027
	By: Age/sex: Male 18-24	13,692
	By: Age/sex: Male 25+	35,817



	Age/Sex: 10-14 Female	74,006
	Age/Sex: 15-17 Female	39,701
	By: Age/sex: 18-24 Female	20,672
	By: Age/sex: 25+ Female	102,597
	Sum of Age/Sex disaggregates	219,061
	Age/Sex: <1	2,853
	Age/Sex: 1-9	103,201
	Program Completion: Active	423,209
	Program Completion: Graduation	74,684
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	65 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	325,130
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	497,893
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,046
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB	87



	cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,533
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	49
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,375
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2
	Aggregated Age/Sex: Male <15 (Numerator: The number of	0



	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	95 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	90,694
	The number of ART patients who were newly started on TB preventive therapy (including those	95,100





	who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
	By Age/Sex (Denominator): <15, Female	5,669
	By Age/Sex (Denominator): <15, Male	5,226
	By Age/Sex (Denominator): 15+, Female	40,861
	By Age/Sex (Denominator): 15+, Male	43,487
	By Age/Sex (Numerator): <15, Female	4,517
	By Age/Sex (Numerator): <15, Male	4,962
	By Age/Sex (Numerator): 15+, Female	40,325
	By Age/Sex (Numerator): 15+, Male	41,043
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	71,969
	TB_PREV_D_DSD_TherapyType_	17,831



	NewExArt_HIV IPT, Life-long ART, New, Positive	
	TB_PREV_N_DSD_TherapyType_ NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
	TB_PREV_N_DSD_TherapyType_ NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
	TB_PREV_N_DSD_TherapyType_ NewExArt_HIV IPT, Life-long ART, Already, Positive	71,459
	TB_PREV_N_DSD_TherapyType_ NewExArt_HIV IPT, Life-long ART, New, Positive	15,364
TB_PREV_TA	TB_PREV_TA TB_PREV_TA	98 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	22,716
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	23,216
	By Age/Sex (Denominator): <15, Female	1,164



	By Age/Sex (Denominator): <15, Male	1,262
	By Age/Sex (Denominator): 15+, Female	9,860
	By Age/Sex (Denominator): 15+, Male	10,001
	By Age/Sex (Numerator): <15, Female	1,125
	By Age/Sex (Numerator): <15, Male	1,269
	By Age/Sex (Numerator): 15+, Female	9,988
	By Age/Sex (Numerator): 15+, Male	10,511
	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	19,180
	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,935
	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New,	0



	Positive	
	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	18,837
	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,860
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	1 %
	Number of ART patients who were started on TB treatment during the reporting period.	4,799
	Number of ART patients who were screened for TB at least once during the reporting period	388,775
	Numerator: By Aggregated Age/Sex: <15, Female	125
	Numerator: By Aggregated Age/Sex: <15, Male	134
	Numerator: By Aggregated Age/Sex: 15+, Female	2,647
	Numerator: By Aggregated Age/Sex: 15+, Male	2,631
	Denominator: By Aggregated Age/Sex: <15, Female	11,343
	Denominator: By Aggregated Age/Sex: <15, Male	12,061
	Denominator: By Aggregated Age/Sex: 15+, Female	179,974
	Denominator: By Aggregated Age/Sex: 15+, Male	185,121
	Denominator: Number of ART patients who had a specimen sent	21,539



	for bacteriologic diagnosis of active TB disease	
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	3,694
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	12,568
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	50,991
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	290,646
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	30,451
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	23,692
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	3,780
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	12,877
	By infants who received a virologic test within 2 months of birth	9,335
	By infants who received their first	3,542



	virologic HIV test between 2 and 12 months of age	
	Sum of Infant Age disaggregates	12,877
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	496
	By infants who received a virologic test within 2 months of birth	400
	By infants who received their first virologic HIV test between 2 and 12 months of age	96
	Sum of Infant Age disaggregates	496
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	494,871
	Age/Sex: 15-19 Male	13,231
	Age/Sex: 15-19 Female	16,419
	Age/Sex: <1	740
	Age/Sex: <1-9	8,723
	Age/Sex: 10-14 Male	9,823
	Age/Sex: 10-14 Female	9,564
	Age/Sex: 20-24 Male	13,796
	Age/Sex: 50+ Male	37,862
	Age/Sex: 20-24 Female	20,322
	Age/Sex: 50+ Female	62,564
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	15,668
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	7,882
	TX_CURR_N_DSD_Age_Sex_HIV	44,063



	Status 30-34, Female, Positive	
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	13,840
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	40,569
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	16,164
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	93,133
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	67,155
	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)
Age/Sex: 15-19 Male		600
Age/Sex: 15-19 Female		749
Sum of Age/Sex disaggregations		1,349
Age/Sex: <1		214
Age/Sex: 1-9		2,996
Age/Sex: 10-14 Male		190
Age/Sex: 10-14 Female		270
Age/Sex: 20-24 Male		618
Age/Sex: 50+ Male		1,694
Age/Sex: 20-24 Female		910
Age/Sex: 50+ Female		2,862
TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive		686
TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive		290
TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive		1,989
TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive		568



	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	1,823
	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	666
	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	4,246
	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	2,965
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	24,153
	By Age/Sex: <1	88
	By Age/Sex: 1-9	575
	By Age/Sex: 10-14 Male	595
	By Age/Sex: 15-19 Male	77
	By Age/Sex: 20-24 Male	480
	By Age/Sex: 50+ Male	1,264
	By Age/Sex: 10-14 Female	1,231
	By Age/Sex: 15-19 Female	364
	By Age/Sex: 20-24 Female	134
	By Age/Sex: 50+ Female	1,834
	Pregnancy status	1,538
	Breastfeeding status	40
	FSW	155
	MSM	0
	People in prisons and other enclosed settings	0
	TG	0
	By Key populations: People who inject drugs (PWID)	0
	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	806
	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	575





	tatus 25-29, Male, Positive	
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	2,274
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	1,099
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	2,117
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	1,243
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	4,813
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	4,430
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,907
	By Age/Sex: <1	57
	By Age/Sex: 1-9	260
	By Age/Sex: 10-14 Male	241
	By Age/Sex: 15-19 Male	4
	By Age/Sex: 20-24 Male	28
	By Age/Sex: 50+ Male	97
	By Age/Sex: 10-14 Female	406
	By Age/Sex: 15-19 Female	28
	By Age/Sex: 20-24 Female	6
	By Age/Sex: 50+ Female	143
	Sum of Age/Sex disaggregates	953
	Pregnancy status	149
	Breastfeeding status	0
	FSW	10
TX_NEW_N_TA_Age_Sex_HIVSta tus 25-29, Female, Positive	55	
TX_NEW_N_TA_Age_Sex_HIVSta	29	



	tus 25-29, Male, Positive	
	TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Female, Positive	168
	TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Male, Positive	61
	TX_NEW_N_TA_Age_Sex_HIVSta tus 35-39, Female, Positive	154
	TX_NEW_N_TA_Age_Sex_HIVSta tus 35-39, Male, Positive	65
	TX_NEW_N_TA_Age_Sex_HIVSta tus 40-49, Female, Positive	358
	TX_NEW_N_TA_Age_Sex_HIVSta tus 40-49, Male, Positive	314
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	433,812
	<15, Undocumented Test Indication, Female	1
	<15, Undocumented Test Indication, Male	0
	15+, Undocumented Test Indication, Female	0
	15+, Undocumented Test Indication, Male	0
	Undocumented Test Indication	0



	Denominator: Indication: Routine	343,881
	Denominator: Indication: Targeted	34,551
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	2,116
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	24,259
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	2,125
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	36,078
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	9,452
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	143,313
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	8,726
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	207,863
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	8,477
	Denominator: Indication: Routine	8,477
	Denominator: Indication: Targeted	0
	<15, Undocumented Test Indication, Female	0



	<15, Undocumented Test Indication, Male	0
	15+, Undocumented Test Indication, Female	0
	15+, Undocumented Test Indication, Male	0
	Undocumented Test Indication	0
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	169
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	41
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	187
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	42
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,093
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	721
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,737
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	488
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	89 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	57,388
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those	64,696



	who have died, those who have stopped ART, and those lost to follow-up	
	Numerator by Status: Pregnant	183
	Numerator by Status: Breastfeeding	189
	Denominator by Status: Pregnant	284
	Denominator by Status: Breastfeeding	151
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,590
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19,327
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,550
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	34,968
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	1,810



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21,908
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,758
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	39,230



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10548	Jimma University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
10557	Mekele University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
10559	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
10599	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	400,000



10601	Addis Ababa University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
11033	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	200,000
11040	United Nations High Commissioner for Refugees	Multi-lateral Agency	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	770,072
12319	Federal Police, Ethiopia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
13770	Harari Regional Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
13794	Oromia Health Bureau, Ethiopia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,799,920





13929	Dire Dawa City Administration Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
13934	Addis Ababa Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,545,678
14267	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs		
16742	National Defense Forces of Ethiopia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16751	Ethiopian Public Health Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
16901	SNNPR	Implementing Agency	U.S. Department of Health and Human Services/Centers	GHP-State	3,208,800



			for Disease Control and Prevention		
16930	FHI 360	NGO	U.S. Agency for International Development	GHP-State	200,000
17271	Ethiopian Society of Sociologists, Social Workers and Anthropologists	NGO	U.S. Agency for International Development	GHP-State	1,000,000
17824	Abt Associates	Private Contractor	U.S. Agency for International Development		
17825	Project HOPE	NGO	U.S. Agency for International Development		
17843	FHI 360	NGO	U.S. Agency for International Development	GHP-State	12,029,711
17856	TBD	TBD	Redacted	Redacted	Redacted
18241	Tera Tech EM, INC	Implementing Agency	U.S. Agency for International Development		
18242	TBD	TBD	Redacted	Redacted	Redacted
18337	Federal Prison Administration of Ethiopia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
18340	Network of Networks of HIV Positives in	Implementing Agency	U.S. Department of Health and Human	GHP-State	1,715,641



	Ethiopia (NEP+)		Services/Centers for Disease Control and Prevention		
18341	TBD	TBD	Redacted	Redacted	Redacted
18375	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	6,972,180
18519	Population Services International	NGO	U.S. Agency for International Development		
70073	TBD	TBD	Redacted	Redacted	Redacted
70074	TBD	TBD	Redacted	Redacted	Redacted
70075	TBD	TBD	Redacted	Redacted	Redacted
70076	Tigray Regional Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,750,000
70077	Amhara Regional Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,900,000
70078	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000



70079	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	375,000
70080	Federal HAPCO	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	350,000
70081	Ethiopian Public Health Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,850,000
70084	TBD	TBD	Redacted	Redacted	Redacted
70087	TBD	TBD	Redacted	Redacted	Redacted
80014	TBD	TBD	Redacted	Redacted	Redacted



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 10548</b>	<b>Mechanism Name: TBD-G2G HIV/AIDS Anti-Retroviral Therapy Programme Implementation Support through Local Universities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Jimma University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	10548	
<b>Mechanism Name:</b>	TBD-G2G HIV/AIDS Anti-Retroviral Therapy Programme Implementation Support through Local Universities	
<b>Prime Partner Name:</b>	Jimma University	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 10557</b>	<b>Mechanism Name: TBD-G2G HIV/AIDS Anti-Retroviral Therapy Program Implementation Support through Local Universities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mekele University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 10557 <b>Mechanism Name:</b> TBD-G2G HIV/AIDS Anti-Retroviral Therapy Program <b>Prime Partner Name:</b> Implementation Support through Local Universities Mekele University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>





Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 10559</b>	<b>Mechanism Name: Peer-to-Peer Capacity Building of Ministries of Health in Public Sector HIV Program Management</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 300,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

## Cross-Cutting Budget Attribution(s)

Gender: GBV	14,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Key Populations: FSW	50,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Adolescent Girls and Young Women (AGYW)	30,000
Human Resources for Health	50,000
Condom programming	5,000



**Budget Code Information**

<b>Mechanism ID:</b>	10559	
<b>Mechanism Name:</b>	Peer-to-Peer Capacity Building of Ministries of Health in Public Sector HIV Program Management	
<b>Prime Partner Name:</b>	National Alliance of State and Territorial AIDS Directors	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	180,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	120,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details



<b>Mechanism ID: 10599</b>	<b>Mechanism Name: Twinning Initiative</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 10599</b>		
<b>Mechanism Name: Twinning Initiative</b>		
<b>Prime Partner Name: American International Health Alliance Twinning Center</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	80,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	320,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 10601</b>	<b>Mechanism Name: G2G-TBD - Addis Ababa University - Strengthening HIV/AIDS, STI &amp; TB Prevention, Care &amp; Treatment Activities</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Addis Ababa University		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>	
<b>Applied Pipeline Amount: 0</b>		
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>		
<b>Funding Source</b>	<b>Funding Amount</b>	

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 10601 <b>Mechanism Name:</b> G2G-TBD - Addis Ababa University - Strengthening HIV/AIDS, STI & TB Prevention, Care & Treatment Activities <b>Prime Partner Name:</b> Addis Ababa University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>





Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details



<b>Mechanism ID: 11033</b>	<b>Mechanism Name: Strengthening PEPFAR Visibility</b>
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 200,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 200,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	200,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	11033	
<b>Mechanism Name:</b>	Strengthening PEPFAR Visibility	
<b>Prime Partner Name:</b>	U.S. Department of State	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	10,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	10,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	170,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	10,000

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 11040</b>	<b>Mechanism Name: HIV in Refugee Camps</b>
Funding Agency: State/PRM	Procurement Type: Grant
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 770,072</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 770,072</b>	
Funding Source	Funding Amount
GHP-State	770,072

### Cross-Cutting Budget Attribution(s)



(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 11040</b>		
<b>Mechanism Name: HIV in Refugee Camps</b>		
<b>Prime Partner Name: United Nations High Commissioner for Refugees</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	39,379
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	9,845
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	39,379
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	113,006
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	63,992
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	164,823
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	319,958
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	19,690

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary	2,688



	medical male circumcision (VMMC) for HIV prevention program within the reporting period	
VMMC_CIRC_DSD	By Age: 2 months - 9 years	1
VMMC_CIRC_DSD	By Age: 10-14	1,729
VMMC_CIRC_DSD	By Age: 15-19	556
VMMC_CIRC_DSD	By Age: 20-24	258
VMMC_CIRC_DSD	By Age: 25-29	134
VMMC_CIRC_DSD	By Age: 50+	10
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	2,553
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	2,687
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	534
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,196
TX_CURR_DSD	Age/Sex: 15-19 Male	62
TX_CURR_DSD	Age/Sex: 15-19 Female	76
TX_CURR_DSD	Sum of age/sex disaggregates	138
TX_CURR_DSD	Age/Sex: <1-9	6
TX_CURR_DSD	Age/Sex: 10-14 Male	29
TX_CURR_DSD	Age/Sex: 10-14 Female	23
TX_CURR_DSD	Age/Sex: 20-24 Male	62
TX_CURR_DSD	Age/Sex: 50+ Male	175
TX_CURR_DSD	Age/Sex: 20-24 Female	94
TX_CURR_DSD	Age/Sex: 50+ Female	294
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	71
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	29
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	207
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	59
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	188



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	70
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	438
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	311
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	114
TX_NEW_DSD	By Age/Sex: 1-9	2
TX_NEW_DSD	By Age/Sex: 10-14 Male	2
TX_NEW_DSD	By Age/Sex: 50+ Male	8
TX_NEW_DSD	By Age/Sex: 10-14 Female	5
TX_NEW_DSD	By Age/Sex: 15-19 Female	1
TX_NEW_DSD	By Age/Sex: 50+ Female	9
TX_NEW_DSD	Sum of Age/Sex disaggregates	25
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	4
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	12
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	4
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	10
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	4
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	25
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	24

### Implementing Mechanism Details

<b>Mechanism ID: 12319</b>	<b>Mechanism Name: Integrated HIV Prevention Program for Federal Police Force of Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement





Prime Partner Name: Federal Police, Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 300,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Water	5,131

**Budget Code Information**

<b>Mechanism ID:</b>	12319	
<b>Mechanism Name:</b>	Integrated HIV Prevention Program for Federal Police Force of Ethiopia	
<b>Prime Partner Name:</b>	Federal Police, Ethiopia	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	51,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	21,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	9,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	60,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	144,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	15,000

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	10
PMTCT_ART_DSD	New on ART	2
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	8
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
PMTCT_STAT_TA	Number of new ANC and L&D clients	0
PMTCT_STAT_TA	By Age (Denominator): Unknown Age	0
PMTCT_STAT_TA	By Age (Denominator): <10	0
PMTCT_STAT_TA	By Age (Denominator): 10-14	0
PMTCT_STAT_TA	By Age (Denominator): 15-19	0
PMTCT_STAT_TA	By Age (Denominator): 20-24	0
PMTCT_STAT_TA	By Age (Denominator): 50+	0



PMTCT_STAT_TA	By known positives: <Unknown Age	0
PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	0
PMTCT_STAT_TA	By known positives: 15-19	0
PMTCT_STAT_TA	By known positives: 20-24	0
PMTCT_STAT_TA	By known positives: 50+	0
PMTCT_STAT_TA	By new positives: Unknown Age	0
PMTCT_STAT_TA	By new positives: <10	0
PMTCT_STAT_TA	By new positives: 10-14	0
PMTCT_STAT_TA	By new positives: 15-19	0
PMTCT_STAT_TA	By new positives: 20-24	0
PMTCT_STAT_TA	By new positives: 50+	0
PMTCT_STAT_TA	By new negatives: Unknown Age	0
PMTCT_STAT_TA	By new negatives: <10	0
PMTCT_STAT_TA	By new negatives: 10-14	0
PMTCT_STAT_TA	By new negatives: 15-19	0
PMTCT_STAT_TA	By new negatives: 20-24	0
PMTCT_STAT_TA	By new negatives: 50+	0
PMTCT_STAT_TA	By Age (Numerator): Unknown Age	0
PMTCT_STAT_TA	By Age (Numerator): <10	0
PMTCT_STAT_TA	By Age (Numerator): 10-14	0
PMTCT_STAT_TA	By Age (Numerator): : 15-19	0
PMTCT_STAT_TA	By Age (Numerator): 20-24	0
PMTCT_STAT_TA	By Age (Numerator): 50+	0
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	0
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	0
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	0
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	0



PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	0
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,977
PP_PREV_DSD	Age/sex: 10-14 Male	0
PP_PREV_DSD	Age/sex: 15-19 Male	1,022
PP_PREV_DSD	Age/sex: 20-24 Male	2,370
PP_PREV_DSD	Age/sex: 50+ Male	10
PP_PREV_DSD	Age/sex: 10-14 Female	0
PP_PREV_DSD	Age/sex: 15-19 Female	122



PP_PREV_DSD	Age/sex: 20-24 Female	378
PP_PREV_DSD	Age/sex: 50+ Female	9
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,911
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	21
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	246
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	21
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	246
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	20
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	246
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	20
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	246
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,639
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	44
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	44
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	872
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	13



	Female, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	335
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	34
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	44
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	88
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19,	0



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1,	0





	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	16
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	32
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	0



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC:	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0



HTC_TST_TA	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	54
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	62
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	196
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	202
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	200
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	200
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	191
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	210
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	0



HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	57
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	59
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	98
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male,	0



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0



	Male, Positive	
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male,	0



	Negative	
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Positive	0



	Positive	
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result Unknown Age, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	38
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	63
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	37
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	62
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39,	37





	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	63
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	37
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	62
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	201
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	252
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	201
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	252
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	201
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	3



	Female, Positive	
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	252
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	201
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	252
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	132
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	1
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	0



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown	0



	Sex, Positive	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	190
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	190
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	190
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	190
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	48
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	48



	Negative	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	48
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	48
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	48
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	48
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	48
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	48
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	185
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	179
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	0



	Positive	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	14
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	15
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	15
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49,	15



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Positive	0



	Female, Positive	
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Positive	0
HTS_SELF_TA	HTS_SELF_N_TA	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	0





HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Unassisted	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	242
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	242
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of	193

	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	49
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	193
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	49
GEND_GBV_DSD	Number of people receiving post-GBV care	90
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	19
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	71
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	54
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	3
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	3
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	4
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	18
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	7



GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	5
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	0

	30-34, Male, Physical and/or Emotional Violence	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	0
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	47
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	37
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The	0



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	31
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	24
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	7
PMTCT_EID_DSD	Sum of Infant Age disaggregates	31
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	0
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_TA	Sum of Infant Age disaggregates	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,760
TX_CURR_DSD	Age/Sex: 15-19 Male	22
TX_CURR_DSD	Age/Sex: 15-19 Female	32
TX_CURR_DSD	Sum of age/sex disaggregates	54
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	69
TX_CURR_DSD	Age/Sex: 10-14 Male	40
TX_CURR_DSD	Age/Sex: 10-14 Female	47
TX_CURR_DSD	Age/Sex: 20-24 Male	83
TX_CURR_DSD	Age/Sex: 50+ Male	49
TX_CURR_DSD	Age/Sex: 20-24 Female	209



TX_CURR_DSD	Age/Sex: 50+ Female	58
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	187
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	352
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	186
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	351
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	186
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	352
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	186
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	351
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	213
TX_NEW_DSD	By Age/Sex: <1	1
TX_NEW_DSD	By Age/Sex: 1-9	3
TX_NEW_DSD	By Age/Sex: 10-14 Male	2
TX_NEW_DSD	By Age/Sex: 15-19 Male	3
TX_NEW_DSD	By Age/Sex: 20-24 Male	13
TX_NEW_DSD	By Age/Sex: 50+ Male	0
TX_NEW_DSD	By Age/Sex: 10-14 Female	2
TX_NEW_DSD	By Age/Sex: 15-19 Female	0
TX_NEW_DSD	By Age/Sex: 20-24 Female	0
TX_NEW_DSD	By Age/Sex: 50+ Female	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	20
TX_NEW_DSD	Pregnancy status	13
TX_NEW_DSD	Breastfeeding status	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29,	15



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	33
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	15
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	32
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	15
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	32
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	15
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	32
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,156
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	Denominator: Indication: Routine	3,156
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15	111



	Male Routine	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,812
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	126
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,107
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	205
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	223
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	2
TX_RET_DSD	Denominator by Status: Pregnant	28
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	119
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	76
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0





TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	136
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	76
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	173
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	772
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	74
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	40
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	255
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	403
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	13
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	8
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	59
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	93
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV	0



	Alternative TPT Regimen, Life-long ART, Already, Positive	
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	772
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	173
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	30
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	2,485
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	8
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	22
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	75
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	75
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1,168
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,167
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	55
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	20



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	13
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	22
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	1,466
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	25
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	977
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	17

### Implementing Mechanism Details

<b>Mechanism ID: 13770</b>	<b>Mechanism Name: Support to GOE Regional Health Bureau in Harari</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Harari Regional Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 300,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

### Cross-Cutting Budget Attribution(s)

Gender: GBV	10,560
Focus Area:	GBV Prevention
Sub Area:	Capacity building



Human Resources for Health	150,000
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID: 13770</b>		
<b>Mechanism Name: Support to GOE Regional Health Bureau in Harari</b>		
<b>Prime Partner Name: Harari Regional Health Bureau</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	30,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	30,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	12,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	12,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	198,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	18,000

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received	98



	ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	
PMTCT_ART_DSD	New on ART	29
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	69
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	264
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	264
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	0



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34,	0





	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result <1, Unknown Sex, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male,	0



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 10-14, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 1-9, Unknown Sex, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	0



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result Unknown Age, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29,	0



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	983
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	6



HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	27
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0



	Male, Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	129
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	186
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	11
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female,	0



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	11
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	79
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	38
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	20
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	5
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	11
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39,	13



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	12
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	11
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	13
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	61
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	0





	Positive	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female,	5



	Negative	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	26
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	2



	Female, Positive	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	26
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	26
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	26
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	14
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	14
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	14
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	1
HTS_SELF_TA	HTS_SELF_N_TA	54
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	4
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	4



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	4
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	4
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	6
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	6
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	4
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	4
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	4
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	4
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	2
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	2
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	2
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	4
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Directly-Assisted	54
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Unassisted	0

TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	319
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	323
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	165
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	127
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	14
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	168
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	13
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	128
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	53
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1



TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	27
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	24
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	118
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	94
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	24
PMTCT_EID_DSD	Sum of Infant Age disaggregates	118
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,404
TX_CURR_DSD	Age/Sex: 15-19 Male	118
TX_CURR_DSD	Age/Sex: 15-19 Female	146
TX_CURR_DSD	Sum of age/sex disaggregates	264
TX_CURR_DSD	Age/Sex: <1	4
TX_CURR_DSD	Age/Sex: <1-9	63
TX_CURR_DSD	Age/Sex: 10-14 Male	142
TX_CURR_DSD	Age/Sex: 10-14 Female	142
TX_CURR_DSD	Age/Sex: 20-24 Male	121
TX_CURR_DSD	Age/Sex: 50+ Male	332
TX_CURR_DSD	Age/Sex: 20-24 Female	178
TX_CURR_DSD	Age/Sex: 50+ Female	559
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	133



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	57
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	389
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	110
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	358
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	130
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	831
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	591
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	84
TX_CURR_TA	Age/Sex: 15-19 Male	2
TX_CURR_TA	Age/Sex: 15-19 Female	3
TX_CURR_TA	Sum of Age/Sex disaggregations	5
TX_CURR_TA	Age/Sex: 1-9	1
TX_CURR_TA	Age/Sex: 10-14 Male	2
TX_CURR_TA	Age/Sex: 10-14 Female	2
TX_CURR_TA	Age/Sex: 20-24 Male	2
TX_CURR_TA	Age/Sex: 50+ Male	6
TX_CURR_TA	Age/Sex: 20-24 Female	3
TX_CURR_TA	Age/Sex: 50+ Female	11
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	3
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	1
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	8
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	2



	Positive	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	7
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	3
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	16
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	12
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	87
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	9
TX_NEW_DSD	By Age/Sex: 10-14 Male	4
TX_NEW_DSD	By Age/Sex: 15-19 Male	1
TX_NEW_DSD	By Age/Sex: 20-24 Male	1
TX_NEW_DSD	By Age/Sex: 50+ Male	2
TX_NEW_DSD	By Age/Sex: 10-14 Female	13
TX_NEW_DSD	By Age/Sex: 15-19 Female	0
TX_NEW_DSD	By Age/Sex: 20-24 Female	1
TX_NEW_DSD	By Age/Sex: 50+ Female	5
TX_NEW_DSD	Sum of Age/Sex disaggregates	27
TX_NEW_DSD	Pregnancy status	0
TX_NEW_DSD	Breastfeeding status	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	7
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	5
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39,	5





	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	15
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	13
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	19
TX_NEW_TA	By Age/Sex: 1-9	1
TX_NEW_TA	By Age/Sex: 50+ Male	1
TX_NEW_TA	By Age/Sex: 10-14 Female	1
TX_NEW_TA	By Age/Sex: 50+ Female	2
TX_NEW_TA	Sum of Age/Sex disaggregates	4
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	1
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	2
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	1
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	2
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	1
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	4
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	3
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	4,045
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0



TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	Denominator: Indication: Routine	3,428
TX_PVLS_DSD	Denominator: Indication: Targeted	617
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	21
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	231
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	21
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	344
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	89
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,306
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	80
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,953
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	385
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	416
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	4
TX_RET_DSD	Denominator by Status: Pregnant	0
TX_RET_DSD	Denominator by Status: Breastfeeding	4
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of	127

	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	236
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	138
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	255
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,173
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period	1,204



	and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	60
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	60
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	542
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	542
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	58
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	58
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	530
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	527
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,000
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	204
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	975
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	198
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	51
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,842



TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	23
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	26
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	115
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	115
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1,807
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,805
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	192
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	38
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	154
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	3,265
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	347
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	192
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	38

### Implementing Mechanism Details

<b>Mechanism ID: 13794</b>	<b>Mechanism Name: Oromia Regional Health Bureau HIV/AIDS program</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Oromia Health Bureau, Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: Yes	Managing Agency: HHS/CDC
<b>Total All Funding Sources: 6,799,920</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 549,388</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 7,349,308</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,799,920

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	60,000
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Water	55,000
Adolescent Girls and Young Women (AGYW)	60,000
Human Resources for Health	100,000

**Budget Code Information**

<b>Mechanism ID: 13794</b>		
<b>Mechanism Name: Oromia Regional Health Bureau HIV/AIDS program</b>		
<b>Prime Partner Name: Oromia Health Bureau, Ethiopia</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	494,827
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HVTB	315,659
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	328,753
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	432,565
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	225,612
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	762,168
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	3,638,188
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	602,148

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,982
PMTCT_ART_DSD	New on ART	595
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,387
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	6,668
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,668
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	40,936





HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	965
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	802
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	349
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	284
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	524
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	480
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	107
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	107
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0



HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,446
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	19
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	172
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	172
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	279
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	230
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	553
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	53
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	507



HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	46
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	108
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	95
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	106
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	2,472
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	66
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	3,058
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	74
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	184
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	187



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	555
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	37
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	371
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	25
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	747
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	50
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	744
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	47
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	2,124
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	52
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	2,761
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29,	200



	Female, Positive	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	1,473
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	109
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	197
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	744
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	54
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	1,111
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	81
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	921
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	64
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	740
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	54
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	922
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	63
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	547
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male,	623



	Negative	
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	447
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	383
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	446
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	384
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	323
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	470
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	508
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	13
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown	0



	Sex, Positive	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	28
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	19
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	128
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	81
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	188
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male,	152



	Negative	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	138
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	169
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	139
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	168
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	165
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	198
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	31
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	31
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	0





	Positive	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	565
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	65
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	566
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	56
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	554
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	56
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	547
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	48
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	290
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	20
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	282
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49,	275



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	15
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	272
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	10
HTS_SELF_TA	HTS_SELF_N_TA	960
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	60
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	49
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	91
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	84
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	94



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	107
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	78
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	67
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	77
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	67
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	59
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	83
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	20
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Unassisted	0



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	21
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Directly-Assisted	957
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Unassisted	3
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Other	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Self	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	421
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest People in prisons and other enclosed settings, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest People in prisons and other enclosed settings, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest PWID, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest PWID, Unassisted	0



	Unassisted	
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest TG, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest TG, Unassisted	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	101
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	265
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	53
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	38
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	11
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	137
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	11
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	105
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,183



TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	5,213
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	246
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	288
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,432
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,189
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	288
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,168
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	245
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,415
GEND_GBV_DSD	Number of people receiving post-GBV care	2,824
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,120
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,683
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,109
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	14
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	14



GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	109
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	115
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	132
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	48
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	187
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	436
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	127
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	289
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	542
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	7
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	14
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	60
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	296
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	0



	25-29, Male, Sexual Violence (Post-Rape Care)	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	47
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	50
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	43
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	42
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	42
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	41
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	881
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	45
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with	419





	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	18
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	402
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,175
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,737
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	438
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,175
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	208
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	168
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	40
PMTCT_EID_TA	Sum of Infant Age disaggregates	208
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	122,629
TX_CURR_DSD	Age/Sex: 15-19 Male	3,239
TX_CURR_DSD	Age/Sex: 15-19 Female	4,018
TX_CURR_DSD	Sum of age/sex disaggregates	7,257
TX_CURR_DSD	Age/Sex: <1	134
TX_CURR_DSD	Age/Sex: <1-9	3,772
TX_CURR_DSD	Age/Sex: 10-14 Male	2,326
TX_CURR_DSD	Age/Sex: 10-14 Female	2,415
TX_CURR_DSD	Age/Sex: 20-24 Male	3,315



TX_CURR_DSD	Age/Sex: 50+ Male	9,026
TX_CURR_DSD	Age/Sex: 20-24 Female	4,915
TX_CURR_DSD	Age/Sex: 50+ Female	15,164
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3,668
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,612
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	10,600
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3,028
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	9,729
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,579
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	22,562
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	16,079
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,544
TX_CURR_TA	Age/Sex: 15-19 Male	68
TX_CURR_TA	Age/Sex: 15-19 Female	86
TX_CURR_TA	Sum of Age/Sex disaggregations	154
TX_CURR_TA	Age/Sex: 1-9	37
TX_CURR_TA	Age/Sex: 10-14 Male	42
TX_CURR_TA	Age/Sex: 10-14 Female	26
TX_CURR_TA	Age/Sex: 20-24 Male	71
TX_CURR_TA	Age/Sex: 50+ Male	195
TX_CURR_TA	Age/Sex: 20-24 Female	104
TX_CURR_TA	Age/Sex: 50+ Female	327
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	79



TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	33
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	228
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	74
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	208
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	76
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	485
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	345
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,036
TX_NEW_DSD	By Age/Sex: <1	25
TX_NEW_DSD	By Age/Sex: 1-9	159
TX_NEW_DSD	By Age/Sex: 10-14 Male	140
TX_NEW_DSD	By Age/Sex: 15-19 Male	8
TX_NEW_DSD	By Age/Sex: 20-24 Male	52
TX_NEW_DSD	By Age/Sex: 50+ Male	201
TX_NEW_DSD	By Age/Sex: 10-14 Female	335
TX_NEW_DSD	By Age/Sex: 15-19 Female	51
TX_NEW_DSD	By Age/Sex: 20-24 Female	11
TX_NEW_DSD	By Age/Sex: 50+ Female	306
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,104
TX_NEW_DSD	Pregnancy status	353
TX_NEW_DSD	Breastfeeding status	1
TX_NEW_DSD	FSW	22
TX_NEW_DSD	MSM	0
TX_NEW_DSD	People in prisons and other enclosed settings	0
TX_NEW_DSD	TG	0



TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	126
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	62
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	365
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	132
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	343
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	156
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	792
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	699
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	100
TX_NEW_TA	By Age/Sex: <1	6
TX_NEW_TA	By Age/Sex: 1-9	17
TX_NEW_TA	By Age/Sex: 10-14 Male	16
TX_NEW_TA	By Age/Sex: 15-19 Male	2
TX_NEW_TA	By Age/Sex: 20-24 Male	2
TX_NEW_TA	By Age/Sex: 50+ Male	10
TX_NEW_TA	By Age/Sex: 10-14 Female	25
TX_NEW_TA	By Age/Sex: 15-19 Female	4
TX_NEW_TA	By Age/Sex: 20-24 Female	2
TX_NEW_TA	By Age/Sex: 50+ Female	15
TX_NEW_TA	Sum of Age/Sex disaggregates	76
TX_NEW_TA	Pregnancy status	5
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	4



TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	2
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	12
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	4
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	11
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	4
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	26
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	20
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	106,283
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	1
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	Denominator: Indication: Routine	90,213
TX_PVLS_DSD	Denominator: Indication: Targeted	12,611
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	528
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	6,062
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	531
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	9,012
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,337



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	34,344
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,128
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	51,309
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	16,506
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	20,839
TX_RET_DSD	Numerator by Status: Pregnant	30
TX_RET_DSD	Numerator by Status: Breastfeeding	32
TX_RET_DSD	Denominator by Status: Pregnant	50
TX_RET_DSD	Denominator by Status: Breastfeeding	25
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	456
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,499
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	442
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,180
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	589
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	6,912



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	563
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,773
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	10,425
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	10,704
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	538
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,015
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	4,360
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	4,831
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	523
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	989
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	4,230
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	4,682
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already,	0



	Positive	
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	8,883
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,821
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	8,649
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,778
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	19,573
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	20,971
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	1,054
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	1,152
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	8,894
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	9,034
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	968
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	1,112
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	8,582





TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	9,107
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	17,387
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,568
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	16,236
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,328
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	1,310
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	102,342
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	27
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	38
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	647
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	596
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,076
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,655
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	47,581
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	48,025
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	5,168
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	6
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,651
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	6,567
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	78,798
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	8,261



TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	4,632
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	1,029

### Implementing Mechanism Details

<b>Mechanism ID: 13929</b>	<b>Mechanism Name: Dire-Dawa Health Bureau HIV/AIDS program</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Dire Dawa City Administration Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 300,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

### Cross-Cutting Budget Attribution(s)

Gender: GBV	40,000
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Sub Area:	Implementation
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	150,000



**Budget Code Information**

<b>Mechanism ID:</b> 13929		
<b>Mechanism Name:</b> Dire-Dawa Health Bureau HIV/AIDS program		
<b>Prime Partner Name:</b> Dire Dawa City Administration Health Bureau		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	30,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	30,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	12,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	15,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	196,500
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	16,500

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	145
PMTCT_ART_DSD	New on ART	39



PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	106
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	792
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	792
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,945
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	25
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	25
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	43
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	33
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	86
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female,	5



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	76
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	63
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	91
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	72
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	72
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	221



HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	149
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	298
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	298
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	38
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	1,100
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	73
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	594
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	44
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	77
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	298
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	22



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	447
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	32
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	370
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	25
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	298
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	21
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	370
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	25
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	102
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	14





HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	8
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	53
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	32
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	73
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	60
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	58
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	68
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	3



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	58
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	69
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	71
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	81
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	15
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	16
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	83



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	84
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	84
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	85
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	12
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	43
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	43
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	44
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	45
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	6
HTS_SELF_TA	HTS_SELF_N_TA	158
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male,	0



	Directly-Assisted	
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	9
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	9
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	15
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	18
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	12
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	9
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	14
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	3
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Directly-Assisted	158
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Unassisted	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,028
TB_STAT_TA	Total number of registered new and relapsed TB cases,	1,039

	during the reporting period.	
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	40
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	40
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	418
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	541
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	40
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	535
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	39
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	414
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	145
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	75

	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	65
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	178
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	140
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	38
PMTCT_EID_DSD	Sum of Infant Age disaggregates	178
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	8,231
TX_CURR_DSD	Age/Sex: 15-19 Male	226
TX_CURR_DSD	Age/Sex: 15-19 Female	280
TX_CURR_DSD	Sum of age/sex disaggregates	506
TX_CURR_DSD	Age/Sex: <1	4
TX_CURR_DSD	Age/Sex: <1-9	179
TX_CURR_DSD	Age/Sex: 10-14 Male	98
TX_CURR_DSD	Age/Sex: 10-14 Female	132
TX_CURR_DSD	Age/Sex: 20-24 Male	235
TX_CURR_DSD	Age/Sex: 50+ Male	643
TX_CURR_DSD	Age/Sex: 20-24 Female	344
TX_CURR_DSD	Age/Sex: 50+ Female	1,078
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	258
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	110



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	751
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	210
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	689
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	250
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,602
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,142
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	82
TX_CURR_TA	Age/Sex: 15-19 Male	2
TX_CURR_TA	Age/Sex: 15-19 Female	3
TX_CURR_TA	Sum of Age/Sex disaggregations	5
TX_CURR_TA	Age/Sex: 10-14 Male	3
TX_CURR_TA	Age/Sex: 10-14 Female	2
TX_CURR_TA	Age/Sex: 20-24 Male	2
TX_CURR_TA	Age/Sex: 50+ Male	6
TX_CURR_TA	Age/Sex: 20-24 Female	3
TX_CURR_TA	Age/Sex: 50+ Female	11
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	3
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	2
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	7
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	2
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	7



TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	2
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	16
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	11
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	700
TX_NEW_DSD	By Age/Sex: <1	1
TX_NEW_DSD	By Age/Sex: 1-9	1
TX_NEW_DSD	By Age/Sex: 10-14 Male	0
TX_NEW_DSD	By Age/Sex: 15-19 Male	0
TX_NEW_DSD	By Age/Sex: 20-24 Male	13
TX_NEW_DSD	By Age/Sex: 50+ Male	43
TX_NEW_DSD	By Age/Sex: 10-14 Female	10
TX_NEW_DSD	By Age/Sex: 15-19 Female	13
TX_NEW_DSD	By Age/Sex: 20-24 Female	1
TX_NEW_DSD	By Age/Sex: 50+ Female	62
TX_NEW_DSD	Sum of Age/Sex disaggregates	142
TX_NEW_DSD	Pregnancy status	163
TX_NEW_DSD	FSW	20
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	26
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	16
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	77
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	29
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	69
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	32





TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	162
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	145
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	21
TX_NEW_TA	By Age/Sex: 1-9	1
TX_NEW_TA	By Age/Sex: 10-14 Male	1
TX_NEW_TA	By Age/Sex: 50+ Male	1
TX_NEW_TA	By Age/Sex: 10-14 Female	1
TX_NEW_TA	By Age/Sex: 50+ Female	2
TX_NEW_TA	Sum of Age/Sex disaggregates	5
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	1
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	2
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	1
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	2
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	1
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	4
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	4
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	7,819
TX_PVLS_DSD	Denominator: Indication: Routine	6,633
TX_PVLS_DSD	Denominator: Indication: Targeted	1,186
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	39
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	444



	Male Targeted	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	39
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	664
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	171
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,527
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	155
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,780
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	973
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,053
TX_RET_DSD	Numerator by Status: Pregnant	4
TX_RET_DSD	Numerator by Status: Breastfeeding	9
TX_RET_DSD	Denominator by Status: Pregnant	16
TX_RET_DSD	Denominator by Status: Breastfeeding	12
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	321
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on	595



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	348
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	644
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	3,311
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	3,398
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	169
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	169
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,533

TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,527
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	165
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	165
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,492
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,489
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,819
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	579
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,749
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	562
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	106
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	8,380
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	2
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	2
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	48
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	54
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	251
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	251
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	3,935
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	3,943
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	419
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	86
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	333
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV	7,121



	Life-long ART, Already, TB Screen - Negative, Positive	
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	755
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	419
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	85

### Implementing Mechanism Details

<b>Mechanism ID: 13934</b>	<b>Mechanism Name: Strengthening local ownership for sustainable provision of HIV/AIDS services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Addis Ababa Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 3,545,678</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 625,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,170,678</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,545,678

### Cross-Cutting Budget Attribution(s)

Key Populations: FSW	21,693
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Water	30,000



Adolescent Girls and Young Women (AGYW)	24,044
Human Resources for Health	1,500,000
Food and Nutrition: Policy, Tools, and Service Delivery	15,000

**Budget Code Information**

<b>Mechanism ID:</b>	13934	
<b>Mechanism Name:</b>	Strengthening local ownership for sustainable provision of HIV/AIDS services	
<b>Prime Partner Name:</b>	Addis Ababa Health Bureau	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	343,156
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	283,156
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	186,578
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	64,122
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	50,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0



Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	611,309
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,501,045
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	506,312

## Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,204
PMTCT_ART_DSD	New on ART	649
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,555
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,228
PMTCT_ART_TA	New on ART	420
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	808
PrEP_NEW_DSD	Male 20-24	0
PrEP_NEW_DSD	Male 50+	0
PrEP_NEW_DSD	Female 15-19	0
PrEP_NEW_DSD	Female 20-24	0
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	0
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	0
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	0
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,239
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,239
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	32,587





HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	24
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	79
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	64
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	115
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	106
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	25
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	25
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	37
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	0



HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	87
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	120
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	141
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	128
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	282
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	259
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	54
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	54
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0



	Female, Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	55
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,708
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	38
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,661
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	34
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	279
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	279
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	839
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	48
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	557
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	31
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female,	1,114



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	68
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,114
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	68
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	1,003
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	21
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	4,096
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	260
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	2,232
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	139
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	279
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	13
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	1,114
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	68



	Positive	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	1,674
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	103
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	1,393
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	88
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	1,114
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	68
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	1,393
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	88
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	122
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	138
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	100
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	86
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39,	100



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	86
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	73
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	106
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	38
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	22
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	0



	Positive	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	133
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	83
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	187
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	157
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	142
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	172
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	142
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	172



	Negative	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	376
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	188
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	31
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	31
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	283
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	11
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	283
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	11





	Positive	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	283
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	11
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	283
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	142
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	142
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	142
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	142
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,401
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,428
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	140
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	1,761



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	140
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,370
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	138
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,779
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	138
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,355
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	403
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	404
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	16
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	16
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	161
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	209



TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	16
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	209
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	16
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	161
GEND_GBV_DSD	Number of people receiving post-GBV care	1,442
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	566
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	851
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	648
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	12
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	13
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	53
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	55
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	59
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	22
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	78
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	218
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	50
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	154
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	286
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	4



GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	12
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	26
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	151
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	24
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	24
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	23
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	24
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	24



	40-49, Female, Sexual Violence (Post-Rape Care)	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	Number of people receiving post-GBV care	694
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	275
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	413
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	275
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	2
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	<10, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	26
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	26
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	41
GEND_GBV_TA	10-14, Male, Sexual Violence (Post-Rape Care)	13
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	46
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	111
GEND_GBV_TA	15-19, Male, Physical and/or Emotional Violence	41
GEND_GBV_TA	15-19, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	68
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	139
GEND_GBV_TA	20-24, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	20-24, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	50+, Female, Physical and/or Emotional Violence	3
GEND_GBV_TA	50+, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_TA	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29,	13



	Female, Physical and/or Emotional Violence	
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	68
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	1
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	13
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	13
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	GEND_GBV_N_TA_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	11



TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2



PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,886
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,153
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,733
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,886
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	288
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	232
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	56
PMTCT_EID_TA	Sum of Infant Age disaggregates	288
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	86,487
TX_CURR_DSD	Age/Sex: 15-19 Male	2,412
TX_CURR_DSD	Age/Sex: 15-19 Female	2,994
TX_CURR_DSD	Sum of age/sex disaggregates	5,406
TX_CURR_DSD	Age/Sex: <1	59
TX_CURR_DSD	Age/Sex: <1-9	311
TX_CURR_DSD	Age/Sex: 10-14 Male	1,474
TX_CURR_DSD	Age/Sex: 10-14 Female	1,473
TX_CURR_DSD	Age/Sex: 20-24 Male	2,475
TX_CURR_DSD	Age/Sex: 50+ Male	6,820
TX_CURR_DSD	Age/Sex: 20-24 Female	3,658
TX_CURR_DSD	Age/Sex: 50+ Female	11,463
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,748
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,186
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	7,978





TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,269
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	7,314
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,669
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	17,047
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	12,140
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	17,514
TX_CURR_TA	Age/Sex: 15-19 Male	485
TX_CURR_TA	Age/Sex: 15-19 Female	603
TX_CURR_TA	Sum of Age/Sex disaggregations	1,088
TX_CURR_TA	Age/Sex: <1	203
TX_CURR_TA	Age/Sex: 1-9	2,953
TX_CURR_TA	Age/Sex: 10-14 Male	102
TX_CURR_TA	Age/Sex: 10-14 Female	203
TX_CURR_TA	Age/Sex: 20-24 Male	499
TX_CURR_TA	Age/Sex: 50+ Male	1,366
TX_CURR_TA	Age/Sex: 20-24 Female	734
TX_CURR_TA	Age/Sex: 50+ Female	2,308
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	552
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	233
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	1,603
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	449
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	1,470



TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	537
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	3,425
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	2,381
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,980
TX_NEW_DSD	By Age/Sex: <1	5
TX_NEW_DSD	By Age/Sex: 1-9	51
TX_NEW_DSD	By Age/Sex: 10-14 Male	43
TX_NEW_DSD	By Age/Sex: 15-19 Male	6
TX_NEW_DSD	By Age/Sex: 20-24 Male	57
TX_NEW_DSD	By Age/Sex: 50+ Male	168
TX_NEW_DSD	By Age/Sex: 10-14 Female	91
TX_NEW_DSD	By Age/Sex: 15-19 Female	52
TX_NEW_DSD	By Age/Sex: 20-24 Female	17
TX_NEW_DSD	By Age/Sex: 50+ Female	251
TX_NEW_DSD	Sum of Age/Sex disaggregates	685
TX_NEW_DSD	Pregnancy status	232
TX_NEW_DSD	Breastfeeding status	2
TX_NEW_DSD	FSW	20
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	113
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	61
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	304
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	110
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	275
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	122



	Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	663
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	591
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,012
TX_NEW_TA	By Age/Sex: <1	42
TX_NEW_TA	By Age/Sex: 1-9	189
TX_NEW_TA	By Age/Sex: 10-14 Male	174
TX_NEW_TA	By Age/Sex: 15-19 Male	2
TX_NEW_TA	By Age/Sex: 20-24 Male	14
TX_NEW_TA	By Age/Sex: 50+ Male	51
TX_NEW_TA	By Age/Sex: 10-14 Female	291
TX_NEW_TA	By Age/Sex: 15-19 Female	12
TX_NEW_TA	By Age/Sex: 20-24 Female	3
TX_NEW_TA	By Age/Sex: 50+ Female	76
TX_NEW_TA	Sum of Age/Sex disaggregates	623
TX_NEW_TA	Pregnancy status	104
TX_NEW_TA	Breastfeeding status	0
TX_NEW_TA	FSW	9
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	28
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	14
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	94
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	31
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	84
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	34



TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	199
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	177
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	76,519
TX_PVLS_DSD	Denominator: Indication: Routine	76,519
TX_PVLS_DSD	Denominator: Indication: Targeted	48
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	383
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	4,364
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	383
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	6,500
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,683
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	24,718
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,531
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	36,953
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	8,477
TX_PVLS_TA	Denominator: Indication: Routine	8,477
TX_PVLS_TA	Denominator: Indication: Targeted	0
TX_PVLS_TA	<15, Undocumented Test Indication, Female	0
TX_PVLS_TA	<15, Undocumented Test Indication, Male	0
TX_PVLS_TA	15+, Undocumented Test Indication, Female	0
TX_PVLS_TA	15+, Undocumented Test Indication, Male	0



TX_PVLS_TA	Undocumented Test Indication	0
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	169
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	41
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	187
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	42
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,093
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	721
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,737
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	488
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,964
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,684
TX_RET_DSD	Numerator by Status: Pregnant	47
TX_RET_DSD	Numerator by Status: Breastfeeding	16
TX_RET_DSD	Denominator by Status: Pregnant	51
TX_RET_DSD	Denominator by Status: Breastfeeding	18
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	253
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,960
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number	245

	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,502
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	279
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,210
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	265
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,948
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	67

HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	56
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	100
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	92
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	103
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	121
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	86
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	74
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	86
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	74
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	92
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	18
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	12,777
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period	12,786



	but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,610
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	734
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	4,761
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	5,641
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	642
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	631
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	5,753
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	5,766
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	10,639
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,189
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	10,508
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,223
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	346
TB_PREV_TA	The number of ART patients who were newly started on	346





	TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	17
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	17
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	152
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	152
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	17
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	17
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	156
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	156
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	286
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	59
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	279
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	57
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	615



TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	49,280
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	17
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	15
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	295
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	288
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,426
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,424
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	23,216
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	23,215
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2,296
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	8,301
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	33,193
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	38,860
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	4,131
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	2,305
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	459

### Implementing Mechanism Details

<b>Mechanism ID: 14267</b>	<b>Mechanism Name: Infrastructure development for health systems strengthening</b>
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14267	
<b>Mechanism Name:</b>	Infrastructure development for health systems strengthening	
<b>Prime Partner Name:</b>	Regional Procurement Support Office/Frankfurt	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 16742</b>	<b>Mechanism Name: Comprehensive HIV Prevention, Care and Treatment for the National Defense Force of Ethiopia (NDFE)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Defense Forces of Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b>	16742	
<b>Mechanism Name:</b>	Comprehensive HIV Prevention, Care and Treatment for the	
<b>Prime Partner Name:</b>	National Defense Force of Ethiopia (NDFE)	
	National Defense Forces of Ethiopia	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	58
PMTCT_ART_DSD	New on ART	46
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	12



PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	15,000
PP_PREV_DSD	Age/sex: 10-14 Male	0
PP_PREV_DSD	Age/sex: 15-19 Male	1,038
PP_PREV_DSD	Age/sex: 20-24 Male	4,442
PP_PREV_DSD	Age/sex: 50+ Male	160
PP_PREV_DSD	Age/sex: 10-14 Female	0
PP_PREV_DSD	Age/sex: 15-19 Female	87
PP_PREV_DSD	Age/sex: 20-24 Female	530
PP_PREV_DSD	Age/sex: 50+ Female	39
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,296
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	218
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	1,958
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	218
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	1,958
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	218
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	1,958
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	218
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,958
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,041
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	181
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	181
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	0





HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,359
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	36
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	907
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	91
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	181
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	363
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	2



HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	34
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	68
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age,	0



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	108
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	108
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,404
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	540
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	0



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	54
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	108
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	216
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	6
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	324
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	26
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	405
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	39
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	324
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	26
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male,	405



	Negative	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	39
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	324
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	26
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	405
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	39
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	324
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	26
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	405
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	39
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	545
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	680
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	545
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	680
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	11



	Positive	
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	545
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	680
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	546
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	681
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	369
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Negative	83
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Negative	83
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Negative	83
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female,	0



	Negative	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	167
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	1,084
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	36
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	417
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	14
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	250
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	312
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	250
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	312
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	11



	Positive	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	250
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	9
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	313
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	250
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	313
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	42
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29,	31





	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	12
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	31
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	12
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	32
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	32
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	1
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	366
TB_STAT_DSD	Total number of registered new and relapsed TB cases,	31



	during the reporting period.	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	53
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	22
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9
GEND_GBV_DSD	Number of people receiving post-GBV care	100
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	96
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	100
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0



GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	59
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	10
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	25
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	0

GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	10
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	25
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	11
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	25
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	10
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	25
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	92
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	77



	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	58
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	47
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	11
PMTCT_EID_DSD	Sum of Infant Age disaggregates	58
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,803
TX_CURR_DSD	Age/Sex: 15-19 Male	34
TX_CURR_DSD	Age/Sex: 15-19 Female	51
TX_CURR_DSD	Sum of age/sex disaggregates	85
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	75
TX_CURR_DSD	Age/Sex: 10-14 Male	55
TX_CURR_DSD	Age/Sex: 10-14 Female	42
TX_CURR_DSD	Age/Sex: 20-24 Male	111
TX_CURR_DSD	Age/Sex: 50+ Male	645
TX_CURR_DSD	Age/Sex: 20-24 Female	126
TX_CURR_DSD	Age/Sex: 50+ Female	161
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	446
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	929



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	447
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	929
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	447
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	929
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	446
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	930
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	597
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	8
TX_NEW_DSD	By Age/Sex: 10-14 Male	4
TX_NEW_DSD	By Age/Sex: 15-19 Male	0
TX_NEW_DSD	By Age/Sex: 20-24 Male	34
TX_NEW_DSD	By Age/Sex: 50+ Male	23
TX_NEW_DSD	By Age/Sex: 10-14 Female	12
TX_NEW_DSD	By Age/Sex: 15-19 Female	0
TX_NEW_DSD	By Age/Sex: 20-24 Female	29
TX_NEW_DSD	By Age/Sex: 50+ Female	6
TX_NEW_DSD	Sum of Age/Sex disaggregates	108
TX_NEW_DSD	Pregnancy status	35
TX_NEW_DSD	Breastfeeding status	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	18
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	102
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	19



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	102
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	19
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	102
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	19
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	102
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,405
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	Denominator: Indication: Routine	5,405
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,800
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	65



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,540
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	573
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	623
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	40
TX_RET_DSD	Denominator by Status: Pregnant	39
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	431
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	121
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	467
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total	14



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	133
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	484
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,158
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	20
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	13
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	512
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,613
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	5
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	3
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	115
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	362
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT,	0



	Life-long ART, Already, Positive	
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,158
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	484
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	0
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	6,123
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	0
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	78
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	99
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1,904
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	4,042
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	245
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	14
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	216
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	15
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV	0



	Life-long ART, Already, TB Screen - Negative, Positive	
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	0
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	5,878
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	245

**Implementing Mechanism Details**

<b>Mechanism ID: 16751</b>	<b>Mechanism Name: Strengthening Capacity for Laboratory Systems, Strategic Information, and Technical Leadership in Public Health for the National HIV/AIDS Response in Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ethiopian Public Health Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 16751</b>
----------------------------



<b>Mechanism Name:</b> Strengthening Capacity for Laboratory Systems, Strategic <b>Prime Partner Name:</b> Information, and Technical Leadership in Public Health for the National HIV/AIDS Response in Ethiopia Ethiopian Public Health Institute		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 16901</b>	<b>Mechanism Name: Strengthening local ownership for sustainable provision of HIV/AIDS services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: SNNPR	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
<b>Total All Funding Sources: 3,208,800</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 200,000</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 3,408,800</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,208,800

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	92,500
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: MSM and TG	100,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Renovation	150,000
Condom programming	50,000
Adolescent Girls and Young Women (AGYW)	80,000
Human Resources for Health	1,110,000
Water	28,300

**Budget Code Information**

<b>Mechanism ID:</b>	16901	
<b>Mechanism Name:</b>	Strengthening local ownership for sustainable provision of	
<b>Prime Partner Name:</b>	HIV/AIDS services	
	SNNPR	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	266,046
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	306,433
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	135,922
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	354,832
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	50,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	515,245
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,273,904
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	306,418

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	665
PMTCT_ART_DSD	New on ART	213
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	452
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	48,576
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	0



HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	542
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	443
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	804
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	743
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	169
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	169
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	369
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	487
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0





HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	97
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	97
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	165
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	135
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	334
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	19
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	299
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	69
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	69



HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	69
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,169
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	31
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,236
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	32
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	382
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	22
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	382
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	22
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,144
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	67
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	761



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	46
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,523
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	95
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,523
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	95
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	1,157
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	30
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	5,716
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	352
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	3,046
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	189
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	382
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	22



	Female, Positive	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	1,523
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	93
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	2,284
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	140
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	1,907
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	117
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	1,523
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	95
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	1,907
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	117
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	847
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	11
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	969
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	694
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male,	593



	Negative	
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	694
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	593
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	497
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	736
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	297
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Positive	0



	Positive	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	70
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	45
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	248
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	151
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	345
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	289
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	258
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male,	316



	Negative	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	258
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	316
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	306
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	379
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	60
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	60
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Positive	0



	Male, Positive	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	334
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	334
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	19
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	333
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	327
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	19
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	165
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	165
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	165
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	165
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	7
HTS_SELF_TA	HTS_SELF_N_TA	324





HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	32
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	26
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	48
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	43
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	48
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	55
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	41



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	34
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	41
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	35
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	29
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	43
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	10
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	10
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Female, Unassisted	0



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Directly-Assisted	324
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Other	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Self	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	497
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest People in prisons and other enclosed settings, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest People in prisons and other enclosed settings, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest PWID, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest PWID, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest TG, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest TG, Unassisted	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,778
TB_STAT_DSD	Total number of registered new and relapsed TB cases,	3,813



	during the reporting period.	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	156
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,944
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	156
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,522
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	156
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,985
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	156
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,516
GEND_GBV_DSD	Number of people receiving post-GBV care	664
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	262
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	402
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	295
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0



GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	23
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	22
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	36
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	43
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	113
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	37
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	83
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	142
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	11
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	78
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	0



GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	277
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	134



	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	136
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	920
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	737
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	183
PMTCT_EID_DSD	Sum of Infant Age disaggregates	920
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	40,234
TX_CURR_DSD	Age/Sex: 15-19 Male	1,067
TX_CURR_DSD	Age/Sex: 15-19 Female	1,313
TX_CURR_DSD	Sum of age/sex disaggregates	2,380
TX_CURR_DSD	Age/Sex: <1	102
TX_CURR_DSD	Age/Sex: <1-9	1,992
TX_CURR_DSD	Age/Sex: 10-14 Male	699
TX_CURR_DSD	Age/Sex: 10-14 Female	615
TX_CURR_DSD	Age/Sex: 20-24 Male	1,128
TX_CURR_DSD	Age/Sex: 50+ Male	3,024
TX_CURR_DSD	Age/Sex: 20-24 Female	1,613
TX_CURR_DSD	Age/Sex: 50+ Female	5,029
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,212
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	519



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	3,512
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,074
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,221
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,231
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	7,477
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	5,378
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,865
TX_NEW_DSD	By Age/Sex: <1	14
TX_NEW_DSD	By Age/Sex: 1-9	54
TX_NEW_DSD	By Age/Sex: 10-14 Male	117
TX_NEW_DSD	By Age/Sex: 15-19 Male	30
TX_NEW_DSD	By Age/Sex: 20-24 Male	118
TX_NEW_DSD	By Age/Sex: 50+ Male	214
TX_NEW_DSD	By Age/Sex: 10-14 Female	124
TX_NEW_DSD	By Age/Sex: 15-19 Female	65
TX_NEW_DSD	By Age/Sex: 20-24 Female	28
TX_NEW_DSD	By Age/Sex: 50+ Female	289
TX_NEW_DSD	Sum of Age/Sex disaggregates	985
TX_NEW_DSD	Pregnancy status	356
TX_NEW_DSD	FSW	33
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	116
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	95
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	334





TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	269
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	318
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	281
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	718
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	681
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	35,840
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	Denominator: Indication: Routine	30,397
TX_PVLS_DSD	Denominator: Indication: Targeted	5,441
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	177
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,043
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	178
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,043
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	784
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	11,535
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	752



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	17,305
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,686
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,775
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	0
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	175
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,839
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	171
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,501
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	160
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,009
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total	157



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,449
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	12,839
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	13,179
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	659
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	657
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	5,934
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	5,929
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	642
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	643
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	5,775
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	5,779
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT,	10,939



	Life-long ART, Already, Positive	
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,240
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	10,663
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	2,176
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	462
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	39,695
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	10
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	10
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	210
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	232
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,087
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,084
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	18,761
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	18,763
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,801
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	14
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	356
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,431
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV	33,956



	Life-long ART, Already, TB Screen - Negative, Positive	
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	3,571
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	1,805
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	363

**Implementing Mechanism Details**

<b>Mechanism ID: 16930</b>	<b>Mechanism Name: Household Economic Strengthening</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 200,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 200,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	200,000

**Cross-Cutting Budget Attribution(s)**

Economic Strengthening	200,000
------------------------	---------

**Budget Code Information**

<b>Mechanism ID: 16930</b>
----------------------------



<b>Mechanism Name: Household Economic Strengthening</b>		
<b>Prime Partner Name: FHI 360</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	200,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17271</b>	<b>Mechanism Name: Local Capacity Building</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Ethiopian Society of Sociologists, Social Workers and Anthropologists	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 1,000,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,000,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,000,000

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	46,223
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	953,777

**Budget Code Information**

<b>Mechanism ID:</b>	17271	
<b>Mechanism Name:</b>	Local Capacity Building	
<b>Prime Partner Name:</b>	Ethiopian Society of Sociologists, Social Workers and Anthropologists	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	1,000,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>





Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17824</b>	<b>Mechanism Name: Private Health Sector Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 17824 <b>Mechanism Name:</b> Private Health Sector Project <b>Prime Partner Name:</b> Abt Associates		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17825</b>	<b>Mechanism Name: USAID Community HIV Care and Treatment (CHCT)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Project HOPE	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17825</b>		
<b>Mechanism Name: USAID Community HIV Care and Treatment (CHCT)</b>		
<b>Prime Partner Name: Project HOPE</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
HTS_SELF_DSD	HTS_SELF_N_DSD	1,700
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	143
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	86
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	178
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	97
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	194
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	101
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	195
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	102
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	181
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	100
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	149



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	100
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	47
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	27
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	1,700

### Implementing Mechanism Details

<b>Mechanism ID: 17843</b>	<b>Mechanism Name: USAID Caring for Vulnerable Children</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 12,029,711</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 12,029,711</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	12,029,711

### Cross-Cutting Budget Attribution(s)

Gender: GBV	190,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Human Resources for Health	100,000
Economic Strengthening	2,020,000





Adolescent Girls and Young Women (AGYW)	1,386,338
Water	100,300

**Budget Code Information**

<b>Mechanism ID: 17843</b>		
<b>Mechanism Name: USAID Caring for Vulnerable Children</b>		
<b>Prime Partner Name: FHI 360</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	12,029,711
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	497,893
OVC_SERV_DSD	Age/Sex: 10-14 Male	68,327
OVC_SERV_DSD	Age/Sex: 15-17 Male	37,027
OVC_SERV_DSD	By: Age/sex: Male 18-24	13,692
OVC_SERV_DSD	By: Age/sex: Male 25+	35,817
OVC_SERV_DSD	Age/Sex: 10-14 Female	74,006
OVC_SERV_DSD	Age/Sex: 15-17 Female	39,701
OVC_SERV_DSD	By: Age/sex: 18-24 Female	20,672
OVC_SERV_DSD	By: Age/sex: 25+ Female	102,597
OVC_SERV_DSD	Sum of Age/Sex disaggregates	219,061
OVC_SERV_DSD	Age/Sex: <1	2,853
OVC_SERV_DSD	Age/Sex: 1-9	103,201
OVC_SERV_DSD	Program Completion: Active	423,209
OVC_SERV_DSD	Program Completion: Graduation	74,684
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	325,130
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	497,893

### Implementing Mechanism Details

Mechanism ID: 17856	TBD: Yes
<b>REDACTED</b>	

### Implementing Mechanism Details

Mechanism ID: 18241	Mechanism Name: Infrastructure Program - Engineering
Funding Agency: USAID	Procurement Type: Contract

Approved



Prime Partner Name: Tera Tech EM, INC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18241</b>		
<b>Mechanism Name: Infrastructure Program - Engineering</b>		
<b>Prime Partner Name: Tera Tech EM, INC</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18242</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18337</b>	<b>Mechanism Name: Comprehensive HIV/AIDS Services for Delivery for Inmates in the Federal Prison Administration</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Federal Prison Administration of Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 250,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 50,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	250,000



**Cross-Cutting Budget Attribution(s)**

Gender: GBV	25,000
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Sub Area:	Implementation
Water	2,000

**Budget Code Information**

<b>Mechanism ID:</b>	18337	
<b>Mechanism Name:</b>	Comprehensive HIV/AIDS Services for Delivery for Inmates in the Federal Prison Administration	
<b>Prime Partner Name:</b>	Federal Prison Administration of Ethiopia	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	37,500
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	25,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	75,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	112,500
Strategic Area	Budget Code	Planned Amount





Treatment	PDTX	0
-----------	------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3
PMTCT_ART_DSD	New on ART	3
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	10,000
PP_PREV_DSD	Age/sex: 10-14 Male	0
PP_PREV_DSD	Age/sex: 15-19 Male	766
PP_PREV_DSD	Age/sex: 20-24 Male	3,373
PP_PREV_DSD	Age/sex: 50+ Male	930
PP_PREV_DSD	Age/sex: 10-14 Female	0
PP_PREV_DSD	Age/sex: 15-19 Female	100
PP_PREV_DSD	Age/sex: 20-24 Female	150
PP_PREV_DSD	Age/sex: 50+ Female	172
PP_PREV_DSD	Sum of Age/Sex disaggregates	5,491
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	54
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	1,073
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	54
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	1,073
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	54
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	1,074
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	53
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,074
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12	3,410



	months	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	49
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	24
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	214
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	43
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown	0



	Age, Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	21
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	40
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	135
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	64
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	29
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	623
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male,	35



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	16
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	134
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	23
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	8
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	26
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	26



HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	112
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	18
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	9
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	0



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	25
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	9
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	25
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	10
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	25
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	10
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	25
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	18
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	47



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	18
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	47
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	18
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	47
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	19
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	48
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	27
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Positive	0



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	24
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	12
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	105
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	9
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	23





HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	9
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	23
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	9
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	24
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	9
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	24
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	3
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	21
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	0



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	53
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	138
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	53
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	138
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	53
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	7
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	138
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	54



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	138
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	5
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	133
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	206
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	120
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	172
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	34
GEND_GBV_DSD	Number of people receiving post-GBV care	50



GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	48
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	2
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	50
GEND_GBVDSD	<10, Female, Physical and/or Emotional Violence	0
GEND_GBVDSD	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	10-14, Female, Physical and/or Emotional Violence	0
GEND_GBVDSD	10-14, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	10-14, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	10-14, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	0
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	15-19, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	15-19, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	0
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	5
GEND_GBVDSD	20-24, Male, Physical and/or Emotional Violence	28
GEND_GBVDSD	20-24, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	50+, Female, Physical and/or Emotional Violence	0
GEND_GBVDSD	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBVDSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0



GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	5
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	5
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	12
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	5
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	10
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	5
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	10
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	33

	during TB treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	31
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	296
TX_CURR_DSD	Age/Sex: 15-19 Male	10
TX_CURR_DSD	Age/Sex: 15-19 Female	0
TX_CURR_DSD	Sum of age/sex disaggregates	10
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	0
TX_CURR_DSD	Age/Sex: 10-14 Male	0
TX_CURR_DSD	Age/Sex: 10-14 Female	0
TX_CURR_DSD	Age/Sex: 20-24 Male	15



TX_CURR_DSD	Age/Sex: 50+ Male	38
TX_CURR_DSD	Age/Sex: 20-24 Female	9
TX_CURR_DSD	Age/Sex: 50+ Female	0
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	4
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	52
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	52
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	4
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	52
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	4
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	52
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	43
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	0
TX_NEW_DSD	By Age/Sex: 10-14 Male	0
TX_NEW_DSD	By Age/Sex: 15-19 Male	6
TX_NEW_DSD	By Age/Sex: 20-24 Male	4
TX_NEW_DSD	By Age/Sex: 50+ Male	0
TX_NEW_DSD	By Age/Sex: 10-14 Female	0
TX_NEW_DSD	By Age/Sex: 15-19 Female	0
TX_NEW_DSD	By Age/Sex: 20-24 Female	0
TX_NEW_DSD	By Age/Sex: 50+ Female	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	10
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29,	2



	Female, Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	6
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	6
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	7
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	6
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	157
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	Denominator: Indication: Routine	157
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15	0





	Male Routine	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	151
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	6
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	41
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	45
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	34
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	38



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	35
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	153
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	0
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	0
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	34
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	119
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	0
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	9
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	26
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0



TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	44
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	109
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	35
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	4
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	266
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	2
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	2
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	20
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	246
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	13
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	3
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	10
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	226
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	24
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	13



TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	3
-----------	---	---

**Implementing Mechanism Details**

<b>Mechanism ID: 18340</b>	<b>Mechanism Name: Peer-to-Peer Support for ART adherence, Retention in Care, Linkage to HIV services and Linkage of Families and Contacts to HIV Testing Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Network of Networks of HIV Positives in Ethiopia (NEP+)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,715,641</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 875,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,590,641</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,715,641

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	5,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building

**Budget Code Information**

<b>Mechanism ID: 18340</b>
----------------------------



<b>Mechanism Name:</b> Peer-to-Peer Support for ART adherence,Retention in <b>Prime Partner Name:</b> Care,Linkage to HIV services and Linkage of Families and Contacts to HIV Testing Services Network of Networks of HIV Positives in Ethiopia (NEP+)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	50,170
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	45,609
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	18,244
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	13,682
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	1,560,571
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	27,365

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

Mechanism ID: 18341	TBD: Yes
REDACTED	

### Implementing Mechanism Details



<b>Mechanism ID: 18375</b>	<b>Mechanism Name: Global Health Supply Chain Program</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 6,972,180</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 5,637,723</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 12,609,903</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,972,180

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18375	
<b>Mechanism Name:</b>	Global Health Supply Chain Program	
<b>Prime Partner Name:</b>	Global Health Supply Chain Program	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	584,434
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	116,887
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	292,097
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	735,743
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	100,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	175,329
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0





Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,383,256
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	584,434

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18519</b>	<b>Mechanism Name: Comprehensive HIV Services for KP &amp; PP</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount

### Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18519</b>		
<b>Mechanism Name: Comprehensive HIV Services for KP &amp; PP</b>		
<b>Prime Partner Name: Population Services International</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a	82,095



	standardized HIV prevention intervention including the minimum components during the reporting period.	
PP_PREV_DSD	Age/sex: 15-19 Male	829
PP_PREV_DSD	Age/sex: 20-24 Male	13,829
PP_PREV_DSD	Age/sex: 50+ Male	829
PP_PREV_DSD	Age/sex: 15-19 Female	8,231
PP_PREV_DSD	Age/sex: 20-24 Female	8,231
PP_PREV_DSD	Sum of Age/Sex disaggregates	31,949
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	8,231
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	14,780
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	8,231
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	12,317
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	829
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	4,114
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,644
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	16,418
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	16,418
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	30,390
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	227
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	87
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male,	4



	Positive	
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	812
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	133
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	98
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	88
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	427
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	682
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	402
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	242
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24,	884



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	402
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	163
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	162
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	85
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	511
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	1,167
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	298
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	1,463
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	79



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	445
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	732
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	295
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: <1, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	1,048
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	1,208
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34,	322



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	1,122
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	321
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	1,282
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	165
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	905
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	135
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	807
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	136
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	2





	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	674
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	232
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	92
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	2,336
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	122
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	451
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	2,491
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	124
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	601
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39,	2,198



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	110
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	449
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	1,463
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	300
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	15
GEND_GBV_DSD	Number of people receiving post-GBV care	1,024
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	508
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	516
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	51
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	49
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	132
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	134
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	109
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	115
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	99
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	98
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	93
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3	96



	35-39, Female, Sexual Violence (Post-Rape Care)	
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	24
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	24
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0
OVC_SERV_DSD	By: Age/sex: Male 18-24	0
OVC_SERV_DSD	By: Age/sex: 18-24 Female	0
OVC_SERV_DSD	Program Completion: Active	0
HTS_SELF_DSD	HTS_SELF_N_DSD	3,289
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	129
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	658
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	757
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	657
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	497
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	461
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	130
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	3,289

### Implementing Mechanism Details

Mechanism ID: 70073	TBD: Yes
<b>REDACTED</b>	

### Implementing Mechanism Details



<b>Mechanism ID: 70074</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 70075</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 70076</b>	<b>Mechanism Name: [Placeholder - 70076 Ethiopia HHS/CDC]</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tigray Regional Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

Key Populations: FSW	20,000
Focus Area:	Training of health workers and community outreach workers
Gender: GBV	21,721
Focus Area:	GBV Prevention
Sub Area:	Capacity building



Human Resources for Health	410,000
Water	21,400
Adolescent Girls and Young Women (AGYW)	55,000

**Budget Code Information**

<b>Mechanism ID:</b> 70076		
<b>Mechanism Name:</b> [Placeholder - 70076 Ethiopia HHS/CDC]		
<b>Prime Partner Name:</b> Tigray Regional Health Bureau		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	250,800
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	59,500
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	90,800
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	150,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	43,900
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	1,021,800
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	133,200

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,271
PMTCT_ART_DSD	New on ART	361
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	910
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,790
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	4,790



	the minimum standards required)	
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,071
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	71
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	70
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	119
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	97
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	241
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	216
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female,	48





	Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	41
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	46
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	925
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	980
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	21
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	64
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	43



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	87
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	87
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	1,011
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	22
HTC_TST_TA	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	326
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	22
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	174
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34,	22



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	87
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	134
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	109
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	87
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	109
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Positive	0



	Positive	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	9
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	17
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	10
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	10
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	11



	Negative	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	10
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	11
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	11
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	17
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Positive	0



	Male, Positive	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	245
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	59
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	245
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	45
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	239
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	17
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	238
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	122
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	119
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	118
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	114
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	1
HTS_SELF_TA	HTS_SELF_N_TA	958



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	61
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	52
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	93
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	84
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	97
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	108
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	76



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	68
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	75
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	68
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	56
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	81
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	20
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	19
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Male, Unassisted	0





HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Directly-Assisted	958
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Other	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Self	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	958
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest People in prisons and other enclosed settings, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest People in prisons and other enclosed settings, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest PWID, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest PWID, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest TG, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest TG, Unassisted	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,052
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	4,102
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	161



TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	161
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,771
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,139
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	156
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,116
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	156
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,622
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	573
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	282
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	7



	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	270
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,550
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,237
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	313
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,550
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	46,090
TX_CURR_DSD	Age/Sex: 15-19 Male	1,259
TX_CURR_DSD	Age/Sex: 15-19 Female	1,567
TX_CURR_DSD	Sum of age/sex disaggregates	2,826
TX_CURR_DSD	Age/Sex: <1	85
TX_CURR_DSD	Age/Sex: <1-9	682
TX_CURR_DSD	Age/Sex: 10-14 Male	966
TX_CURR_DSD	Age/Sex: 10-14 Female	977
TX_CURR_DSD	Age/Sex: 20-24 Male	1,307
TX_CURR_DSD	Age/Sex: 50+ Male	3,570
TX_CURR_DSD	Age/Sex: 20-24 Female	1,918
TX_CURR_DSD	Age/Sex: 50+ Female	6,004
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,434
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	610
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	4,176
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,179



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	3,833
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,393
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	8,927
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	6,354
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	433
TX_CURR_TA	Age/Sex: 15-19 Male	12
TX_CURR_TA	Age/Sex: 15-19 Female	15
TX_CURR_TA	Sum of Age/Sex disaggregations	27
TX_CURR_TA	Age/Sex: 1-9	1
TX_CURR_TA	Age/Sex: 10-14 Male	12
TX_CURR_TA	Age/Sex: 10-14 Female	13
TX_CURR_TA	Age/Sex: 20-24 Male	12
TX_CURR_TA	Age/Sex: 50+ Male	33
TX_CURR_TA	Age/Sex: 20-24 Female	18
TX_CURR_TA	Age/Sex: 50+ Female	56
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	13
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	6
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	39
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	11
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	36
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	13
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female,	83



	Positive	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	59
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	964
TX_NEW_DSD	By Age/Sex: <1	7
TX_NEW_DSD	By Age/Sex: 1-9	57
TX_NEW_DSD	By Age/Sex: 10-14 Male	32
TX_NEW_DSD	By Age/Sex: 15-19 Male	1
TX_NEW_DSD	By Age/Sex: 20-24 Male	14
TX_NEW_DSD	By Age/Sex: 50+ Male	37
TX_NEW_DSD	By Age/Sex: 10-14 Female	132
TX_NEW_DSD	By Age/Sex: 15-19 Female	10
TX_NEW_DSD	By Age/Sex: 20-24 Female	3
TX_NEW_DSD	By Age/Sex: 50+ Female	58
TX_NEW_DSD	Sum of Age/Sex disaggregates	287
TX_NEW_DSD	Pregnancy status	72
TX_NEW_DSD	Breastfeeding status	0
TX_NEW_DSD	FSW	1
TX_NEW_DSD	MSM	0
TX_NEW_DSD	People in prisons and other enclosed settings	0
TX_NEW_DSD	TG	0
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	27
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	20
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	79
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	43
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	77



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	48
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	165
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	152
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	107
TX_NEW_TA	By Age/Sex: 1-9	3
TX_NEW_TA	By Age/Sex: 10-14 Male	3
TX_NEW_TA	By Age/Sex: 20-24 Male	2
TX_NEW_TA	By Age/Sex: 50+ Male	6
TX_NEW_TA	By Age/Sex: 10-14 Female	4
TX_NEW_TA	By Age/Sex: 15-19 Female	2
TX_NEW_TA	By Age/Sex: 50+ Female	8
TX_NEW_TA	Sum of Age/Sex disaggregates	25
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	4
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	3
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	12
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	4
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	10
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	4
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	22
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	20
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record	43,092



	and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	Denominator: Indication: Routine	34,957
TX_PVLS_DSD	Denominator: Indication: Targeted	6,249
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	211
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,456
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	211
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,656
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	947
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	13,915
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	864
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	20,833
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,905
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,400
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	164
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of	1,952



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	155
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,632
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	180
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,113
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	174
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,925
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	7,667
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period	8,043





	and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	398
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	398
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	3,638
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,609
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	385
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	385
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,544
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	3,518
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	6,675
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,368
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	6,504
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,304
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	537
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	41,001
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	14
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	16
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	257
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	251
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,231
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,231
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	19,268
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	19,269
TX_TB_DSD	Denominator: Number of ART patients who had a	696



	specimen sent for bacteriologic diagnosis of active TB disease	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	2
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	8
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	11,805
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,251
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	696
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	135

**Implementing Mechanism Details**

<b>Mechanism ID: 70077</b>	<b>Mechanism Name: [Placeholder - 70077 Ethiopia HHS/CDC]</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Amhara Regional Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	92,500
Focus Area:	GBV Prevention



Sub Area:	Capacity building
Water	63,000
Human Resources for Health	2,300,000
Food and Nutrition: Policy, Tools, and Service Delivery	20,000
Adolescent Girls and Young Women (AGYW)	25,000

**Budget Code Information**

<b>Mechanism ID:</b> 70077		
<b>Mechanism Name:</b> [Placeholder - 70077 Ethiopia HHS/CDC]		
<b>Prime Partner Name:</b> Amhara Regional Health Bureau		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	614,250
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	226,764
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	236,250
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	75,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	100,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	652,631
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	2,514,001
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	481,104



## Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,292
PMTCT_ART_DSD	New on ART	1,491
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,801
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	6,453
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with	6,453



	individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	109,774
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	74
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	59
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,614
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	30
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,316



HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	26
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,401
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	48
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,220
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	40
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	509
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	507
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	103
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	205
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Negative	214



HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	216
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	354
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	289
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	726
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	78
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	645
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	59
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	147
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	148
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0





	Male, Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	142
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	2,738
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	387
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	3,161
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	395
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	736
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	59
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	737
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	65
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,195
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	175
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,476
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	124
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	2,949
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female,	248



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	2,950
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	248
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	2,917
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	371
HTC_TST_TA	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	11,020
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	872
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	5,896
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	523
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	745
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	93
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male,	2,931



	Negative	
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	237
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	4,390
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	362
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	3,681
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	312
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	2,949
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	248
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	3,686
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	316
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	2,506
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	47
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	2,837
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	54
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	2,065
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	38
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	1,771
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	33



	Positive	
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	2,065
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	40
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	1,771
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	34
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	1,482
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	27
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	2,185
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	40
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	927
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	20
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female,	111



	Negative	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	66
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	390
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	11
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	249
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	552
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	460
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	426
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	11
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	511
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	16



	Positive	
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	424
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	13
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	510
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	469
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	587
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	19
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	98
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	98
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29,	729



	Female, Negative	
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Positive	66
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	728
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Positive	65
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	720
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Positive	56
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	723
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	51
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	368
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	361
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	361
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	13
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	353
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	11
HTS_SELF_TA	HTS_SELF_N_TA	1,231
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	0



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	69
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	63
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	116
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	108
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	123
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	139
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	101
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	0





HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	87
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	101
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	90
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	79
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	106
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	26
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	25
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Female, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Male, Directly-Assisted	0



HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Directly-Assisted	1,141
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Unassisted	90
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Other	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Self	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Directly-Assisted	599
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest FSW, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest MSM, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest People in prisons and other enclosed settings, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest People in prisons and other enclosed settings, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest PWID, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest PWID, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest TG, Directly-Assisted	0
HTS_SELF_TA	HTS_SELF_N_TA_KeyPop_HIVSelfTest TG, Unassisted	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	10,510
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	11,136
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total	496

	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	964
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4,214
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5,741
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	921
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,242
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	459
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,836
GEND_GBV_DSD	Number of people receiving post-GBV care	1,238
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	492
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	744
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	418
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	30



GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	32
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	41
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	88
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	211
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	39
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	178
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	259
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	75
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	179
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	18



GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	27
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	8
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	5
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	7
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	0
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	659
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	317
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The	10



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	321
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,278
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,621
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	657
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,278
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	151,486
TX_CURR_DSD	Age/Sex: 15-19 Male	4,148
TX_CURR_DSD	Age/Sex: 15-19 Female	5,151
TX_CURR_DSD	Sum of age/sex disaggregates	9,299
TX_CURR_DSD	Age/Sex: <1	216
TX_CURR_DSD	Age/Sex: <1-9	1,085
TX_CURR_DSD	Age/Sex: 10-14 Male	3,642
TX_CURR_DSD	Age/Sex: 10-14 Female	3,353
TX_CURR_DSD	Age/Sex: 20-24 Male	4,289
TX_CURR_DSD	Age/Sex: 50+ Male	11,741
TX_CURR_DSD	Age/Sex: 20-24 Female	6,291
TX_CURR_DSD	Age/Sex: 50+ Female	19,723
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	4,779
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,103
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	13,711



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3,988
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	12,672
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	4,807
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	29,128
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	20,630
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,304
TX_CURR_TA	Age/Sex: 15-19 Male	31
TX_CURR_TA	Age/Sex: 15-19 Female	39
TX_CURR_TA	Sum of Age/Sex disaggregations	70
TX_CURR_TA	Age/Sex: <1	11
TX_CURR_TA	Age/Sex: 1-9	4
TX_CURR_TA	Age/Sex: 10-14 Male	29
TX_CURR_TA	Age/Sex: 10-14 Female	24
TX_CURR_TA	Age/Sex: 20-24 Male	32
TX_CURR_TA	Age/Sex: 50+ Male	88
TX_CURR_TA	Age/Sex: 20-24 Female	48
TX_CURR_TA	Age/Sex: 50+ Female	149
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	36
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	15
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	104
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	30
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	95



TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	35
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	221
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	157
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,029
TX_NEW_DSD	By Age/Sex: <1	29
TX_NEW_DSD	By Age/Sex: 1-9	202
TX_NEW_DSD	By Age/Sex: 10-14 Male	206
TX_NEW_DSD	By Age/Sex: 15-19 Male	16
TX_NEW_DSD	By Age/Sex: 20-24 Male	131
TX_NEW_DSD	By Age/Sex: 50+ Male	425
TX_NEW_DSD	By Age/Sex: 10-14 Female	433
TX_NEW_DSD	By Age/Sex: 15-19 Female	129
TX_NEW_DSD	By Age/Sex: 20-24 Female	34
TX_NEW_DSD	By Age/Sex: 50+ Female	633
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,007
TX_NEW_DSD	Pregnancy status	301
TX_NEW_DSD	Breastfeeding status	37
TX_NEW_DSD	FSW	39
TX_NEW_DSD	MSM	0
TX_NEW_DSD	People in prisons and other enclosed settings	0
TX_NEW_DSD	TG	0
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	265
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	136
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	803
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male,	274





	Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	747
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	350
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,657
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,482
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	648
TX_NEW_TA	By Age/Sex: <1	9
TX_NEW_TA	By Age/Sex: 1-9	49
TX_NEW_TA	By Age/Sex: 10-14 Male	47
TX_NEW_TA	By Age/Sex: 15-19 Male	0
TX_NEW_TA	By Age/Sex: 20-24 Male	10
TX_NEW_TA	By Age/Sex: 50+ Male	28
TX_NEW_TA	By Age/Sex: 10-14 Female	84
TX_NEW_TA	By Age/Sex: 15-19 Female	10
TX_NEW_TA	By Age/Sex: 20-24 Female	1
TX_NEW_TA	By Age/Sex: 50+ Female	40
TX_NEW_TA	Sum of Age/Sex disaggregates	220
TX_NEW_TA	Pregnancy status	40
TX_NEW_TA	FSW	1
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	17
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	10
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	46
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	20
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female,	45



	Positive	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	21
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	103
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	90
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	131,473
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	Denominator: Indication: Routine	93,016
TX_PVLS_DSD	Denominator: Indication: Targeted	8,399
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	661
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	7,518
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	666
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	11,157
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,891
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	42,746
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,625
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	63,398
TX_RET_DSD	Number of adults and children who are still alive and on	14,075



	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	15,248
TX_RET_DSD	Numerator by Status: Pregnant	90
TX_RET_DSD	Numerator by Status: Breastfeeding	70
TX_RET_DSD	Denominator by Status: Pregnant	97
TX_RET_DSD	Denominator by Status: Breastfeeding	78
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	383
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,696
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	368
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,612
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	427
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,086
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	414



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,322
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	34,034
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	34,832
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,743
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,742
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	15,733
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	15,718
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,697
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1,695
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	15,323
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	15,315
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	24,722
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	5,053

TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, Already, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV Alternative TPT Regimen, Life-long ART, New, Positive	0
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	25,077
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	4,934
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,797
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,899
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	93
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	93
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	814
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	815
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	140
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	140
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	1,250
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	1,248
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,507
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	308
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,322



TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	475
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	1,430
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	115,601
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	50
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	48
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	1,040
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	1,043
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,407
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,530
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	53,171
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	55,503
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	9,657
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	3,638
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,700
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	8,466
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	98,361
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	10,306
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	5,784
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	1,205

### Implementing Mechanism Details

<b>Mechanism ID: 70078</b>	<b>Mechanism Name: Strengthening Public Health</b>
----------------------------	--



		<b>Capacity and Guidelines to Implement HIV Programs through Cooperation and Support from the WHO under PEPFAR</b>	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: World Health Organization			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	
<b>Total All Funding Sources: 0</b>		<b>Total Mechanism Pipeline: N/A</b>	
<b>Applied Pipeline Amount: 0</b>			
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>			
<b>Funding Source</b>		<b>Funding Amount</b>	

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 70078			
<b>Mechanism Name:</b> Strengthening Public Health Capacity and Guidelines to Implement HIV Programs through Cooperation and Support from			
<b>Prime Partner Name:</b> the WHO under PEPFAR			
World Health Organization			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	
Care	HBHC	0	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	
Care	HKID	0	



Strategic Area	Budget Code	Planned Amount
Care	HVTB	250,000
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount





Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 70079</b>	<b>Mechanism Name: [Placeholder - 70079 Ethiopia HHS/CDC]</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 70079		
<b>Mechanism Name:</b> [Placeholder - 70079 Ethiopia HHS/CDC]		
<b>Prime Partner Name:</b> African Society for Laboratory Medicine		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	175,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	200,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details



<b>Mechanism ID: 70080</b>	<b>Mechanism Name: [Placeholder - 70080 Ethiopia HHS/CDC]</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Federal HAPCO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 70080</b>		
<b>Mechanism Name: [Placeholder - 70080 Ethiopia HHS/CDC]</b>		
<b>Prime Partner Name: Federal HAPCO</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0



Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	350,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 70081</b>	<b>Mechanism Name: [Placeholder - 70081 Ethiopia HHS/CDC]</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ethiopian Public Health Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 70081		
<b>Mechanism Name:</b> [Placeholder - 70081 Ethiopia HHS/CDC]		
<b>Prime Partner Name:</b> Ethiopian Public Health Institute		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	108,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	300,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	200,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	135,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	1,107,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 70084</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	



Approved



### Implementing Mechanism Details

<b>Mechanism ID: 70087</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 80014</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		0		0	204,500	204,500
ICASS		0		0	978,517	978,517
Management Meetings/Professional Development		0		0	199,250	199,250
Non-ICASS Administrative Costs		0		0	194,334	194,334
Staff Program Travel		0	0	0	168,249	168,249
USG Staff Salaries and Benefits - Internationally Recruited		0	0	0	1,194,378	1,194,378
USG Staff Salaries and Benefits - Locally Recruited		0	0	0	1,106,291	1,106,291
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>4,045,519</b>	<b>4,045,519</b>



**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		0		0	44,666	44,666
Management Meetings/Professional Development		0		0	6,147	6,147
Non-ICASS Administrative Costs		0		0	5,500	5,500
Staff Program Travel				0	39,510	39,510
USG Staff Salaries and Benefits - Internationally Recruited				0	54,442	54,442
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>150,265</b>	<b>150,265</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
-------------------------------	-----	-----------	-----------	----------------------	------------------	---



Capital Security Cost Sharing		1,519,200		1,519,200	0	1,519,200
Computers/IT Services		474,100		474,100	0	474,100
ICASS		1,303,400		1,303,400	0	1,303,400
Institutional Contractors				0	0	0
Management Meetings/Professional Development		305,900		305,900	0	305,900
Non-ICASS Administrative Costs		365,350		365,350	0	365,350
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel	0	583,200		583,200	0	583,200
USG Staff Salaries and Benefits - Internationally Recruited	0	1,672,750		1,672,750	0	1,672,750
USG Staff Salaries and Benefits - Locally Recruited	2,787,500	58,600		2,846,100	0	2,846,100
<b>Total</b>	<b>2,787,500</b>	<b>6,282,500</b>	<b>0</b>	<b>9,070,000</b>	<b>0</b>	<b>9,070,000</b>

**U.S. Department of State**

Agency Cost	GAP	GHP-State	GHP-USAID	Funding	Applied	Total All
-------------	-----	-----------	-----------	---------	---------	-----------



of Doing Business				Source Total	Pipeline	Funding Sources and Applied Pipeline Amount
ICASS		66,371		66,371	0	66,371
Management Meetings/Professional Development		20,000		20,000	0	20,000
Non-ICASS Administrative Costs		10,000		10,000	0	10,000
Staff Program Travel		50,000		50,000	0	50,000
USG Staff Salaries and Benefits - Internationally Recruited		373,024		373,024	0	373,024
USG Staff Salaries and Benefits - Locally Recruited		30,000		30,000	142,857	172,857
<b>Total</b>	<b>0</b>	<b>549,395</b>	<b>0</b>	<b>549,395</b>	<b>142,857</b>	<b>692,252</b>